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1.1 Growth hormone secretion
1.1.1 Introduction
Growth hormone (GH) is expressed specifically in the somatotroph cells of the anterior
pituitary gland, and GH secretion by somatotrophs is thought to be central in regulating post¬
natal growth. In particular, GH increases bone mineral density, especially in longitudinal bones
(Longobardi et ah, 1999), but GH also influences many bodily processes that influence body
composition in humans, such as lipid metabolism (Oscarsson et ah, 1989). GH secretion
declines progressively during adulthood, and this decline is especially marked in elderly
subjects. In severe GH deficiency, an individual's muscle mass, muscle strength and bone mass
are decreased, and the relative proportion of total and visceral fat is increased (Johannsson et
ah, 2000). In elderly subject with hypothalamic-pituitary disease and GH deficiency, total fat
mass was significantly higher than in control subjects (Li Voon Chong et ah, 2000). Thus, GH
promotes skeletal growth and promotes muscle growth rather than fat deposition.
In GH-deflcient adults, GH has been applied for therapeutic purposes in order to improve their
quality of life. It was reported that recombinant human GH (rhGH) treatment significantly
increased lean body mass and decreased fat mass in adults with GH deficientcy (Salomon et
ah, 1989). Many of the actions of GH are mediated through insulin-like growth factor-I (IGF-
I), which is increased following GH replacement (Gillberg et ah, 2001). In normal adults,
plasma IGF-I concentrations, like those of GH, significantly decline with age in both sexes
(Yamamoto et ah, 1991). Replacement of low-dose GH produces improvements in body
composition and in quality of life that can be detected as early as 1 month after the start of
treatment, and the beneficial effects continue at 3 months in patients with GH deficiency
(Ahmad et ah, 2001). Recently, long-term effect of GH replacement was found to prevent the
age-related decline in insulin sensivity in GH-deficient adults (Svensson et ah, 2002).
Sensitivity to insulin declines with increasing age especially in GH-deficient adults.
Additionally, GH treatment in GH-deficient children also results in normal bone mineral
density (Fors et ah, 2001)
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Short stature is commonly caused by impairments of either GH secretion or receptor function.
Short stature in children with Prader-Willi syndrome, which may be explained, at least in part,
by a decreased GH secretory capacity, can be effectively treated with exogenous GH for one
year (Hauffa, 1997). GH treatment to correct physical abnormality has to be continued
indefinitely. Linear growth in GH-deficient children is the single most useful parameter
available for evaluating the efficacy of GH replacement therapy (Shalet et al., 1998). In
children with idiopathic short stature, the causes for growth failure are not definitely
established. Plasma GH binding protein activity in children with idiopathic short stature has
been reported to be significantly lower than in a control group (Davila et ah, 1996). GH
binding protein is a soluble form of GH receptor that can bind GH, and the decreased GH
binding protein activity in children with idiopathic short stature suggests that they may present
a degree of GH insensitivity due to a defect at the GH-receptor level. In adults with GH
deficiency, continuation of GH replacement showed improvement in increasing serum insulin¬
like growth factor-I and lean body mass, whereas discontinuation of the treatment increased
total body fat (Norrelund et al., 2000).
GH secretion from the pituitary depends on many factors, including stress (Noel et al., 1972),
acute exercise (Bigbee et al., 2000) and stage of menstrual cycle (Faria et al., 1992). In
somatrotrophs of the anterior pituitary, electron microscopic immunocytochemical studies have
demonstrated that GH is stored in large, dense-cored secretory granules (Hirano and Shiino,
1989). In cultured rat somatotrophs perifused with GHRH, GH release and 45 Ca2+ efflux
appear to be tightly coupled, with the calcium response perhaps slightly preceding GH release
(Ohlsson and Lindstrom, 1990). This suggests that GH is released by exocytosis in a calcium-
dependent manner like other peptide hormones.
The systemic actions of GH may be mediated by GH itself or by GH-induced release of other
peripheral factors, including in particular insulin-like growth factor-I (IGF-I), which is
expressed and produced primarily in liver (Butler et al., 2002). In mice lacking a functional GH
receptor, IGF-I levels could be as low as 0.2 % of normal levels (Lupu et al., 2001). Under
normal conditions, IGF-I is bound in the circulation to specific binding proteins 1-6 (Bach and
Rechler, 1996). Most of circulating IGF-I is bound with IGF-binding protein-3 as a complex
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whereas the remaining IGF-I circulates either free or bound in a complex with one of five other
IGF-binding proteins (Jones and Clemmons, 1995). In children with GH deficiency, serum-
concentrations of free IGF-I are significantly lower than those in age- and sex-matched normal
children (Wacharasindhu et al., 2000). Conversely, administration of GH significantly
increases free IGF-I concentration (Bereket et ah, 1997). These data suggest that serum
concentrations of total IGF-I are GH-dependent and can be used as a screening tool for GH-
deficient status.
Apart from physical improvement, GH therapy with recombinant human GH has been applied
to improve mental performance. Low doses of recombinant human GH significantly improve
psychological profiles as rated by the Hamilton Depression Scale (HDS) in adult-onset patients
with GH deficiency (Takahashi and Chihara, 1999). A significant correlation between increase
in IGF-I concentrations and decrease in HDS scores in recombinant human GH-treated patients
confirmed the improvement of psychological profiles along with physical changes (Giusti et
ah, 1998). However, an effect of GH treatment on psychological profiles has not been
consistently observed. Standardised psychometric tests have been used to measure cognition
and sense of well-being before and after GH therapy. However, following 18 months of GH
replacement therapy, there were no significant alterations in cognitive function or quality of
life assessed by standardised tests in adult men with acquired GH deficiency (Baum et ah,
1998). Another study performed in adults with documented GH deficiency also found no better
psychological response, whereas the improvements in increasing IGF-I concentrations, body
composition and self-perceived well-being were significant (Carroll et ah, 1997).
Thus, GH deficiency, in ageing or in inherited disorders, produces profound physical
impairments and possibly also mental impairments. Accordingly, therapeutic strategies to
provide remedies for GH deficiency have considerable potential benefits for the quality of life
in an ageing population.
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1.1.2 GH secretion in dwarfism
Dwarfism can arise by defects in GH production and release, or by defects in downstream
signalling. In dwarf (dw-/-) chickens, the overall GH mean, amplitude, and baseline
concentrations are significantly higher than those of control normal-sized (Dw+/~) chickens,
and no differences in peak length or peak frequency between genotypes are observed (Buyse et
ah, 1994). By contrast, in the dwarf mouse strain {lit/lit), anterior pituitaries do not release GH
or accumulate cyclic adenosine 3' monophosphate (cyclic AMP) in response to human or rat
GHRH, whereas dibutyryl cyclic AMP, as well as the adenylate cyclase stimulators forskolin
and cholera toxin, markedly stimulate GH release (Jansson et ah, 1986). GH-deficient dwarf
lit/lit mouse is a mutant having a point mutation in the N-terminal ligand-binding domain of
the GHRH receptor (Lin et ah, 1993). This suggests that the basis of the GH deficiency in the
little mouse may be a defect in an early stage of GHRH-stimulated GH release, related either to
receptor binding or to the function of the hormone-receptor complex. In Lewis-derived dwarf
rats, the percentage of pituitary cells that release GH is substantially lower than in normal rats
(Kineman et ah, 1989). In addition, the expression of GHRH-R mRNA in pituitary extracts of
GH-deficient rats, detected by using RNAse protection assay, is markedly reduced in extracts
from age-matched male and female dwarf rats with GH-deficiency (Carmignac et ah, 1996).
Thus, GH secretion in dwarfs is different from in normals due to a variety of defects in the
transduction pathway including defects at the receptor level, cyclic AMP production, and
expression of GHRH-R mRNA, as well as a reduction in the total number of GH-secreting
cells in the pituitary gland.
1.1.3 Pulsatile pattern of GH release
In all species studied to date, GH is released episodically. This pulsatile pattern of secretion is
particularly marked in male rats. (Tannenbaum and Martin, 1976) collected blood samples
every 15 min from male rats and demonstrated pulsatile GH secretion at approximately 3-h
intervals with peak values higher than 200 ng/ml and basal values lower than 1 ng/ml. This
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study also revealed a very constant rhythmic pattern of secretion with a regular time interval
between pulses that was unchanged across all phases of a 12-h light dark cycle.
The effects of sex steroid hormones on GH release suggest sexual dimorphism (Gevers et al.,
1998). In male rats, plasma concentrations of GH are markedly periodic, with high peak but
low basal levels, whereas more continuous secretion and substantially higher basal
concentrations are evident in female rats (Eden, 1979). This sex-related difference is believed
to be an important contributor to the higher growth rate in males of most mammalian species.
In female rats, the interval between GH peaks is shorter than in males and less regularity is
observed, especially in old female rats that show very irregular intervals between peaks. (Eden,
1979).
1.1.4 Physiological significance of pulsatile secretion of GH
The pulsatile pattern of GH secretion was hypothesised to be important in regulating GH-
mediated processes. Pulsatile treatment with exogenous GH (one pulse per 3 h) resulted in 3-
to 5-fold increase in the levels of IGF-I expression in skeletal muscle and rib growth plates of
male rats, while, by contrast, continuous infusion with GH was much less effective (Isgaard et
al., 1988). Pulsatile intravenous infusion of GH-releasing hormone (GHRH) performed to
establish a male type of GH secretory pattern for normal female rats also accelerated growth
and increased pituitary GH content, whereas continuous infusion of this GHRH fragment at the
same daily dose was ineffective (Clark and Robinson, 1985). Pulsatile GH secretion is believed
to be governed mainly by two hypothalamic peptides: a stimulatory factor, GHRH, and an
inhibitory factor, somatostatin. These peptide factors reach the anterior pituitary gland via the
hypophysial portal circulation after release from nerve endings in the median eminence.
Measurement of immunoreactive GHRH and somatostatin concentrations in portal blood found
episodic secretion of immunoreactive GHRH, with maximal concentrations during GH
secretory episodes, and secretion of immunoreactive GHRH was accompanied by a moderate
reduction in portal plasma concentrations of immunoreactive somatostatin (Plotsky and Vale,
1985).
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1.1.5 Hypothalamic control of GH secretion
GHRH is synthesised by a sub-population of neurones in the arcuate nucleus (Jacobowitz et al.,
1983), and somatostatin by a sub-population of neurones in the periventricular nucleus
(Brazeau et al., 1973). These peptides are transported along axons to nerve endings in the
median eminence, and released from nerve terminals into the hypothalamo-hypophysial portal
blood circulation to influence the anterior pituitary gland.
Okada and co-workers collected serial blood samples from unanaesthetised female rats during
electrical stimulation of the periventricular nucleus (Okada et al., 1991). Plasma concentrations
were reduced significantly during stimulation, while a large increase in GH secretion followed
immediately after the end of the stimulation. (Koibuchi et al., 1986) showed that electrical
stimulation of the basolateral amygdala resulted in a significant increase in plasma GH
concentration, and this increase was markedly augmented after lesion of the periventricular
nucleus. This suggests that the basolateral amygdala provides an excitatory drive to GH
secretion, and indicates that the activity of periventricular neurones is inhibitory to this release.
Dickson and co-workers (Dickson et al., 1994) showed that electrical stimulation of the
periventricular nucleus resulted in inhibition of electrical activity of arcuate neurones that were
identified antidromically as projecting to the median eminence, and which were therefore
presumed to be neurosecretory neurones. This inhibition was followed with a rebound
hyperactivation after the end of stimulation.
The electrical stimulation of the periventricular nucleus could result in the release of
somatostatin and thereafter directly modulate GHRH neurones via somatostatin receptors,
which have been localised in the arcuate nucleus (Tannenbaum et al., 1998b). Somatostatin
released from the periventricular nucleus is believed to mediate its effect on GH secretion via
GHRH neurones as well as by actions on somatotrophs. This idea was supported by a study
that demonstrated the existence of both GHRH-expressing neurones and somatostatin binding
sites in the arcuate nucleus (Bertherat et al., 1992).
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Five somatostatin receptor (SSTR) subtypes, SSTR1-5, have been cloned and characterised
(Reisine and Bell, 1995). All five subtypes are functionally coupled to inhibition of adenylyl
cyclase via pertussis toxin sensitive GTP-binding protein (Patel et al., 1995). SSTR2 comprises
SSTR2A and 2B, and can also stimulate tyrosine phosphatase and phospholipase C via
SSTR2A (Delesque et ah, 1995). The biological roles of individual subtypes are still largely
unknown. The distribution of SSTR1 and SSTR2 mRNA-expressing cells in the arcuate
nucleus suggests the involvement of these subtypes in regulation of GHRH secretion (Beaudet
et ah, 1995). Both subtypes are co-localised in GHRH mRNA-containing cells (Tannenbaum et
ah, 1998b). Given the lack of specific receptor antagonists, antisense oligodeoxynucleotides
were used to investigate the specific subtypes that are involved in regulating GHRH secretion.
Only the SSTR1 antisense oligodeoxynucleotides diminished the amplitude of ultradian GH
pulses without modifying their frequency, whereas SSTR2 antisense oligodeoxynucleotides did
not modify the GH secretory pattern (Lanneau et ah, 2000). This study supports a preferential
role of the SSTR1 receptor subtype in the regulation of GH secretion by somatostatin at the
hypothalamus. However, SSTR1 and SSTR2 receptor subtypes may be also involved in other
physiological function since they were also expressed in jejunum, stomach, cerebrum, and
kidney (Yamada et ah, 1992).
In vivo, continuous infusion of GHRH increases nocturnal GH secretion, while the episodic
pattern of GH secretion is maintained (Sassolas et ah, 1986). This study also found that other
parameters, including total sleep time, sleep latency, and duration and timing of the different
sleep stages, were not affected by GHRH infusions. On the other hand, pulsatile secretion of
GH in rats was abolished by the infusion of a monoclonal antibody specific for rat GHRH
(Wehrenberg et ah, 1982). The mechanism of action of GHRH was later investigated using
MZ-4-71, an antagonistic analogue of human GHRH (hGHRH), to block secretion of GH and
IGF-I in rats (Kovacs et ah, 1996). Additionally, a competitive antagonist to the GHRH
receptor (GHRH-Ant) was demonstrated to suppress pulsatile GH secretion in healthy young
men (Jaffe et ah, 1993). This confirms the involvement of GHRH in the generation of GH
pulses in human. Possible neural pathways that connect the arcuate nucleus and the






Fig.1.1. Loci and connections of hypothalamic peptidergic neurones of
the GH neuroendocrine axis.:^cta Paediatr Scand [Suppl] 372: 5-16, 1991.
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Somatostatin also plays a crucial role in governing the periodicity of GH secretion. To
understand the mechanism, pulsatile secretory patterns were established using administration
of various involved peptides especially GHRH and somatostatin, in different ways. Application
of 10-min GHRH pulses every 3-h cycles to dispersed anterior pituitaries (107 cells) generated
consistent peaks of GH release, between 200 and 300 ng/min, and these peaks were not altered
by continuous co-application of somatostatin (Weiss et al., 1987). However, the same study
found that somatostatin withdrawal during GHRH administration elicited markedly higher GH
peaks and more total GH release. In another in vitro study, the burst of GH release after
cessation of perifusion of somatostatin plus GHRH was blocked by the administration of
somatostatin during the burst, while the magnitude of the burst was proportional to the
concentration of GHRH preceding the withdrawal of somatostatin (Kraicer et al., 1988). Thus
the timing and fluctuating pattern of somatostatin release might be key factors that generate
periodicity of GH secretion. Such results led to the hypothesis that the magnitude of the GH
pulses is set by the amount of GHRH impinging on the somatotrophs, while somatostatin
regulates the timing of the episodic bursts ofGH secretion.
Somatostatin withdrawal was thus recognised as a potential generator of pulsatile GH release.
However, somatostatin withdrawal alone exhibited only a small GH rise (maximum GH 2.9 ±
1.2 p.g/1) in normal young men (Ho et al., 1993), indicating that somatostatin withdrawal by
itself is an ineffective promoter of GH release. Periodic quiescence of somatostatin neurones
must be associated with a concomitant GHRH pulse in order to result in a robust GH pulse.
1.2 GH secretagogues
1.2.1 History and development of GH secretagogues
Classically, our understanding of GH release has focussed mainly on the roles of GHRH and
somatostatin. However, other neurosecretory pathways may also play an important role in
regulating GH release.
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In 1976, Cyril Y. Bowers of Tulane University (New Orleans, La., USA) found that some
opioid peptide derivatives had weak GH releasing activity (Bowers et ah, 1980). Following this
observation, many peptide derivatives were synthesised in an attempt to establish more potent
GH-releasing peptides. However, the opiate effect on GH release, though obvious, is not highly
specific as it also releases prolactin (Shaar et al., 1977). In 1981, peptide analogues of the
opiate met-enkephalin were identified that lacked opiate activity, but caused release of GH
(Bowers et al., 1981). Thereafter, met-enkephalin was used as a model for newly synthetic
compounds.
The effect ofmet-enkephalin analogues on GH release was also observed in normal men when
the analogue DAMME [D-Ala2,MePhe4-Met-enkephalin-(o)-ol, FK 33-824] was shown to
enhance GHRH-induced GH release (Delitala et al., 1989). This suggested that the effect of
this analogue may be mediated via a different pathway from GHRH.
Conformational energy calculations, computer modelling, structural modification, and
biological studies were carried out for new compound synthesis. The met-enkephalin analogue
I, Tyr-D-Ala-Gly-Phe-Cys(Et), with an isosteric isomer of methionine in met-enkephalin, was
demonstrated to increase serum concentrations of prolactin and GH in male rats, and this effect
was reversed by simultaneous treatment with the opiate antagonist naloxone (Nedvidkova et
al., 1988). This analogue was more potent than natural met-enkephalin in releasing GH. The
inhibition by naloxone suggested the involvement of opiate pathways in the brain rather than
an action on the hypophysial-pituitary axis.
Progressively more active analogues were designed. Among a series of GH-releasing peptides
(GHRPs), pentapeptide, the His-DTrp-Ala-Trp-DPhe-NH2 (I) and the hexapeptide, His-DTrp-
Ala-Trp-DPhe-Lys-NH2 (II) exhibit in vitro activity at 1-10 ng/ml, and these peptides were
also active in releasing GH in vivo at low microgram dosages (Momany et al., 1984). These
GHRPs lacked any effect on TSH, LH, FSH, and prolactin release.
Due to structural modifications, these enkephalin-derived GH-releasing peptides might have
different binding sites from those of opiates. In binding assays, a series of pentapeptides and
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hexapeptides GHRPs were found to have low potencies at mu and delta opioid binding sites
receptors in forebrain of rats (Codd et al., 1988). Thus, the changes in structure of GHRPs
enhanced GH-releasing activity while decreasing their potency at opioid binding sites.
As new compounds were synthesised that were more potent and more specific in releasing GH
from the pituitary gland, these came to be called "GH secretagogues" (GHSs). The chronology
and structure of various peptidyl and non-peptidyl GH secretagogues is shown in the fig. 1.2


















Fig. 1.2. Chronology and structure of various peptidyl and non-peptidyl GH
secretagogues.: Frontiers in Neuroendocrinology 19,47-72 (1998)
GH secretagogues 15
1.2.2 GHRP-6
The synthetic hexapeptide, His-DTrp-Ala-Trp-Dphe-Lys-NH2 (GHRP-6) was first identified in
1984 (Momany et al., 1984). Its GH releasing activity was very potent in vitro and in vivo in
many species including rat. (Bowers et al., 1984). Intravenous injection or intranasal
administration of GHRP-6 caused a marked increase in plasma GH concentrations, and
enhanced IGF-I production in healthy male subjects (Hayashi et ah, 1991). It was also found to
be orally active in normal men at doses of 100 and 300 mg/kg (Bowers et ah, 1992).
Membrane fragments from both the hypothalamus and anterior pituitary tissues were found to
contain binding sites to GHRP-6 and related peptides, and the bindings of these peptides were
significantly correlated to their potencies in releasing GH (Codd et ah, 1989).
1.2.3 Pituitary mechanism of GHRP-6
Initially, it was unclear whether GHRP-6 and related peptides stimulated GH release via the
same mechanism to that of endogenous GHRH. It was first thought that GHRP-6 acted on the
GHRH pathway since it did not elicit GH release in GH-deficient mice, which are presumed to
have either a deficit in GHRH or a GHRH receptor malfunction (Bowers et ah, 1992). In
addition, hexarelin was unable to increase plasma GH concentration in adult men affected with
GHRH receptor deficiency (Maheshwari et ah, 1999). These in vivo blunted GH responses to
GHRP indicated the involvement of hypothalamic GHRH for the GHRP effect. Alternatively,
the blunted response to GHRP could reflect low or absent pituitary GH stores brought about by
chronic GHRH deficiency, rather than a requirement for acute GHRH involvement. However
in normal men, synergistic GH release was observed following the administration of maximal
doses of GHRP plus GHRH (Bowers et ah, 1990). The synergistic action ofGHRP and GHRH
suggest that they act, at least in part, independently. It proved difficult however to study
independent effects of GHRP or related peptides separately from the effects of GHRH and
other endogenous factors in vivo. A model of acute GHRH deprivation was needed in order to
examine the requirement of GHRH for GHRP action in vivo. However observations of GH
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release at the level of single pituitary cells provided more direct evidence of the cellular effects
ofGHRP.
1.2.4 GHS and GHRH act on different pathways
Although GHRH and GHS both release GH, their actions appeared to be rather unrelated.
GHRP-6 and the later synthesised KP 101, induced GH release when applied to ovine pituitary
cells, and the induction was not affected by a GHRH antagonist ([Ac-Tyrl, D-Arg2]-GHRH 1-
29) which significantly reduced the effect of GHRH on GH release (Wu et al., 1994). The GH
secretory response of pituitary cells desensitises rapidly during continued exposure to either
GHRP or GHRH. Dispersed rat pituitary cells that were desensitised to either GHRP-6 or
GHRH still showed GH release when challenged with the alternate peptide, showing that there
was no cross-desensitisation between them (Blake and Smith, 1991). These findings indicated
that GHRPs act via different receptors from GHRH. In support of this, GHRH was
demonstrated to have additive stimulatory effects with hexarelin in normal rat somatotrophs,
but did not affect hexarelin-stimulated GH release in a GH-secreting rat cell line (GHi) that
lacks GHRH receptors (Giustina et ah, 1997). This finding from a GH-secreting rat cell line
might not represent the mechanism in normal pituitary cells, but it suggests that non-GHRH-
mediated pathways for GHRP action exist. In 12 cell cultures derived from human somatotroph
adenomas, GH secretion could be stimulated with GHRP-6 in all 12 cultures, whereas only 6
cultures responded to GHRH (Renner et ah, 1994). These observations confirm the existence of
a population of GHRP-6-stimulated adenoma cells, which is not dependent on GHRH pathway
in releasing GH.
Thus, the in vivo synergistic action ofGHRP-6 and GHRH suggest that the endogenous GHRH
pathway is not the only pathway that stimulates GH release. The idea of another pathway for
stimulation of GH release was supported when GHRH antagonists failed to block the induction
of GH release by either GHRP-6 or a newly synthesised secretagogue KP-101.
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In a rat model in which GHRH function was impaired by treatment with GHRH antiserum, the
GH secretagogue hexarelin still stimulated GH mRNA expression in the anterior pituitary
(Torsello et ah, 1997). From the binding assay, a significant correlation between the binding
affinity of secretagogues (MK-0677, L-692,429 and the peptides GHRP-6 and hexarelin) and
GH-secretory activity was confirmed; the binding was not displaced by GHRH or by
somatostatin, and it showed the properties of a new G-protein-coupled receptor (Pong et ah,
1996). It was speculated that GH secretagogues mimic an unidentified natural hormone that
regulates GH secretion in concert with GHRH and somatostatin.
The mechanism by which GHRPs elicit GH secretion has been investigated at the level of
intracellular signalling pathways in pituitary cells. GHRP-1, a second generation GHRP, (Ala-
His-D-beta Nal-Ala-Trp-D-Phe-Lys-NH2), induced increases in intracellular [Ca2+] and GH
release in rat pituitary cell cultures like GHRH, but unlike GHRJH, GHRP-1 increases GH via a
2_j_
[Ca ]-dependent and cAMP-independent mechanism (Akrnan et ah, 1993). cAMP is one of
the second messengers believed to mediate part of the effect of GHRH on GH release since
cAMP concentration in rat primary pituitary cell culture was increased by about 3-fold.
However, GHRP-6 had no effect on the basal cAMP level (Cheng et ah, 1989). No effect of
GHRP-6 or other secretagogues on cAMP was observed except GHRP-2 which increased
cAMP concentrations; GHRP-2 had an additive effect with GHRH on both cAMP
concentrations and GH release, whereas its additive effect with GHRP-6 was only on GH
release (Wu et ah, 1996). The additive effects of GHRP-2, GHRH and GHRP-6 suggest that
these three peptides act on different receptors.
The intracellular mechanism of protein kinase C (PKC) pathway of GHRP can be studied by
measuring intracellular free Ca2+ in vitro. When external Ca2+ was removed or when voltage-
gated membrane Ca2+ channels were blocked, GHRP-6 still caused a transient elevation of
intracellular Ca2+ in single rat somatotrophs (Herrington and Hille, 1994), suggesting that
GHRP stimulates the release of Ca2+ from intracellular stores. Additionally, simultaneous
measurement of intracellular Ca2+ and membrane current revealed that the transient release by
GHRP-6 activates a voltage-independent Ca2+-activated K+ conductance (Herrington and Hille,
1994). This rapid transient phase was followed by a persistent phase. It thus seems likely that
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GHRP-6 depolarises somatotrophs, inducing voltage-gated Ca2+ entry, while also acting via
intracellular second messenger pathways to release Ca2+ from intracellular stores, which leads
to increasing K+ conductance and finally transient hyperpolarisation of somatotrophs.
Studies in human somatotrophs have also been performed using cells from human acromegalic
tumours. In tumours in which GH secretion was increased by GHRH and GHRP-2 (a second
generation GHRP) the cAMP antagonist (Rp-cAMP) blocked the GH response to GHRH but
not to GHRP-2, whereas PKC inhibitors attenuated the effect of GHRP-2 on GH secretion but
did not affect the GH response to GHRH (Chen et al., 1998). These findings suggest that
GHRH increases GH secretion from human GH tumours via the cAMP pathway whereas
GHRP-2 increases GH secretion mainly via the PKC pathway.
Based on these findings, GHRPs might act on distinct receptor(s) different from that ofGHRH
to depolarise pituitary cell membranes that lead to opening of Ca2+ channels and to GH release.
In addition, the PKC pathway is activated, and Ca2+ from intracellular stores is released from
intracellular stores, which may also contribute to GH secretion; however intracellular Ca2+ has
many potential actions, including regulation of gene expression.
1.2.5 Effects of GHRP on GH synthesis
Thus GHRP stimulates release of GH; does GHRP also induce GH synthesis? The expression
of GH mRNA, but not prolactin mRNA in monolayer cultures of rat pituitary is increased by
exposure to GHRH (Gick et al., 1984). However, GH mRNA expression was also affected by
other sex steroids when bovine GH content in primary cultures of normal and transformed
tumour cultures of rat pituitary cells was decreased by triiodothyronine (T3) and
dexamethasone which did not alter GH secretion (Silverman et al., 1988). On the other hand,
estradiol had no effect on bovine GH mRNA expression, but increased bovine GH secretion
(Silverman et al., 1988).
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Since both GH mRNA expression and GH release are increased by GHRH, it seems plausible
that GH release is a consequence of GH synthesis following the induction of GH expression.
GHRP was therefore investigated whether it plays a role in the control of GH biosynthesis as
well as release. In vivo, models of reduced GH mRNA expression were needed to investigate
the effects of GHRP. In adult male rats after 5-day pre-treatment with surgical ablation of the
mediobasal hypothalamus, hexarelin did not enhance GH secretion, and on day 7 GHRH was
significantly more effective than hexarelin; on day 30, by which time the mediobasal
hypothalamic function was supposed to recover, hexarelin and GHRH evoked similar rises of
plasma GH (Torsello et al., 1996). These results suggest that hexarelin acts, at least in part, on
the hypothalamus through the release of an unknown hypothalamic factor that elicits GH
release, acting synergisticallywith GHRH.
In infant rats immunised with GHRH antibodies, hexarelin administration for 3-10 days
significantly enhanced the GH response, though mean plasma GH concentrations remained
lower than in control group, and treatment with hexarelin for 3 and 5, but not 10 days, restored
GH mRNA levels to control values (Torsello et al., 1997). Similar effects were observed in
GHRH-antibody passively immunised pups treated with GHRP-6 (Locatelli et al., 1994).
Antibodies against GHRH were used to block GHRH function, while leaving GHRH receptors
intact. In GH deficiency animal model, impairment could be either at level ofGHRH synthesis
or GHRH receptor malfunction, but by using GHRH antibodies, changes in plasma GH
concentrations should reflect the abilities of hexarelin or GHRP-6 in inducing GH mRNA
expression, and thereafter GH release.
These findings suggest that the effects of GHRP on GH release and GH mRNA expression
may be unrelated. Moreover, it is likely that GHRP can stimulate GH mRNA expression
independently of endogenous GHRH. However, the failure of hexarelin to enhance GH release
in adult rats with surgical ablation of mediobasal hypothalamus emphasises the concept that in
vivo, GHRP acts mostly on the hypothalamus.
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1.2.6 Actions of GHRP in the central nervous system
Studies of the effects of GHRP-6 and related peptides have focused on the hypothalamus and
the pituitary gland. The hypothalamus was hypothesised to be a central brain region where
GHRPs could influence the release of GHRH and somatostatin. Central effects of GHRPs in
sheep are inferred by the demonstration of an increase in jugular GH concentrations and a
stimulation of GHRH release into hypophysial portal blood following intravenous injection of
hexarelin (Guillaume et ah, 1994). Measurements ofGHRH in the hypophysial portal blood of
conscious sheep during infusion of GHRP-6 showed a 50 % increase in GHRH pulse
frequency, though the mean plasma GHRH concentrations were not significantly increased.
Such findings indicate that GHRP-induced GH stimulation in the sheep involves activation of
GHRH neurones in addition to its direct effect on pituitary cells.
Systemic (or central) administration ofGHRP-6 resulted in induction of expression of Fos (the
protein product of the c-fos gene) throughout the ventromedial and ventrolateral regions of the
rat arcuate nucleus (Dickson et al., 1993). The induction of Fos expression was highly specific
to the arcuate nucleus; no Fos expression was observed in other hypothalamic regions, though
since these earliest reports subsequent studies have shown that some secretagogues (though not
GHRP-6) induce Fos expression in the supraoptic nucleus, and GHRP-6 and other
secretagogues induce some Fos expression in the nucleus tractus solitarii in the brainstem
(Bailey et ah, 1999b).
The expression of Fos is not secondary to the stimulation of GH secretion, since similar
patterns of Fos expression were observed in GH-deficient "little" (lit/lit) mice in response to
GHRP-6 (Sirinathsinghji et ah, 1995), and systemic (or central) injection of GHRH did not
result in Fos expression, nor did systemic (or central) injection of IGF-1 (Dickson et ah,
1995a). Either intravenous (i.v.) or intracerebroventricular (i.e.v.) injections of GHRP-6
resulted in an increased density of Fos-immunoreactive neurones in the arcuate nucleus, and
these effects were similar to those induced by the non-peptidyl secretagogues (L-692,585 and
L-692,429), whereas no increase in Fos expression was observed in rats given a systemic
injection of a high dose of GHRH (Dickson et ah, 1995b). The failure of systemic injection of
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GHRH to induce Fos expression in the arcuate nucleus implies that GHRP-6-induced Fos in
this region is not mediated by increased plasma concentrations ofGH or GHRH.
More recently, the induction of Fos expression in the arcuate nucleus by systemic injection of
GHRP-6 was reported to be potentiated in fasted rats and this induction was not altered by co¬
administration of leptin (Luckman et al., 1999). This study also found that leptin by itself
induced Fos immunoreactivity in the arcuate nucleus, though not necessarily in the same
neurones as are activated by secretagogues. The detection of electrical responses recorded at
the cell bodies of arcuate neurones of rats injected intravenously with GHRP-6 confirms that
the arcuate nucleus is a central site of action ofGHRP-6 (Dickson et al., 1995b).
The detection of c-fos gene expression has been widely used to determine specific central brain
regions that respond to compound administration. However, it should not be considered an
indicator of a direct site of action, nor should it be considered an infallible marker of activation.
Other neurones in the brain that do not express Fos may also be activated. Moreover, neurones
expressing Fos might be activated indirectly as a result of depression of activity in inhibitory
afferent inputs. Characterising the electrophysiological responses of neuroendocrine arcuate
neurones provides more direct of evidence for central actions of GHRP-6 or other
secretagogues.
1.2.7 Actions of GH secretagogues on secretory neurones in the hypothalamus
Intravenous injection of GHRP-6, resulted in induction of Fos-like immunoreactivity
specifically within the arcuate nucleus of rats, as well as stimulating the electrical activity of a
population of arcuate neurones of rats that were antidromically identified as projecting to the
median eminence (Bailey et al., 1998). Most of the arcuate neurones that expressed Fos in
response to GHRP-6 were also labelled with fluorescence retrograde tracer Fluorogold given
systemically to label neurones that project outside the blood brain barrier (Dickson et al.,
1996). The neuronal activation to the systemic administration of the secretagogue shows that
the action is relatively selective, and occurs mainly in putative neurosecretory neurones.
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In later experiments it was established that the activity of MK-0677-responsive arcuate
neurones was inhibited by systemic somatostatin, whereas the activity of MK-0677-non-
responsive and non-neuroendocrine arcuate neurones was not affected (Bailey et al., 1998).
These findings indicated that secretagogues act specifically on arcuate neurones that regulate
GH secretion from the pituitary gland.
Though the patterns of activation of non-peptidyl secretagogues seen in Fos expression
(Dickson et al., 1995b) and electrical activity (Bailey et ah, 1998) were similar to that of
GHRP-6, the exact mechanism was unclear. L-692,429 is one of a novel non-peptidyl class of
GH secretagogues. It was demonstrated to stimulate GH release from rat primary pituitary
cells, and this effect was inhibited by GHRP-6 antagonist but not by antagonists to GHRH or
opiates (Cheng et ah, 1993). Similarly, L-692,400, an antagonist of L-692,429 and GHRP-6,
antagonised stimulation of GH release caused by GHRP-6 but did not antagonise GHRH
(Smith et ah, 1993). Thus GHRP-6 and L-692,429 apparently act at the same receptors.
Additionally, L-692,429 was found to increase cytosolic free Ca2+ concentration of rat
somatotrophs determined by fluorescence ratio imaging (Smith et ah, 1993).Such data
indicated that the non-peptide secretagogues are mimetics of GHRP-6 based signal
transduction.
1.3 Growth hormone secretagogue receptor
1.3.1 Characterisation of the GHS receptor
In 1989, a significant correlation between binding activity of SK&F110679 to membrane
fragments of both hypothalamus and anterior pituitary, and the release of GH was obtained
(Codd et ah, 1989). Since then, a series of secretagogues (GHSs) and their mimetics have been
designed to have specific effects on GH release. Consistently, the spiroindoline MK-0677, one
of ideal small molecule of GHS, was incorporated with 35S to produce a radioligand with a
high specific activity for binding assays (Pong et ah, 1996). The binding of this ligand to
anterior pituitary membranes is Mg2+-dependent, is inhibited by GTP-y-S, and is competitively
inhibited by benzolactam L-692,429, and by the peptides GHRP-6 and hexarelin, but not by
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GHRH and somatostatin (Pong et al., 1996). High-affinity binding was non-competitively
inhibited by GTP-y-S suggesting that the receptor was G-protein coupled. Additionally, the
inhibition of [35S]MK-0677 binding by GHS but not GHRH or somatostatin implied the
discovery of a new receptor involved in the control of GH release.
In an attempt to isolate the MK-0677 receptor, digitonin was used to solubilise the receptor
from porcine anterior pituitary membranes. The receptor was recovered as a receptor-[35S]MK-
0677-G protein complex that appeared in the digitonin micelle, but the receptor was not
successfully isolated (Pomes et al., 1996). In addition, treatment with GTP- y-S to the
solubilised receptor in the digitonin micelle resulted in dissociation of MK-0677 from the
receptor, whereas treatment with ATP-y-S did not (Pomes et al., 1996). This provided evidence
that the MK-0677 receptor was coupled to a G protein in the soluble complex.
1.3.2 Cloning of the GHS-R
Identification of binding sites of radiolabeled peptide and nonpeptide GHSs in pituitary and
hypothalamic membranes led to attempts to identify, clone and sequence of the GHS receptor
(GHS-R). Xenopus oocytes injected with Size-fractionated polyadenylated [poly(A)+] RNA
isolated from swine pituitary, exhibited oscillatory increases in calcium-activated chloride (CP)
currents induced by MK-0677 or GHRP-6 (Howard et al., 1996), indicating expression of the
GHS-R. The activation of CP currents is presumably based on observations that ligands for the
receptor activated IP3-induced release of intracellular Ca2+. However, positive responses from
injected oocytes of this study were relatively low. Thus, the use of rat pituitary polyadenylated
RNA failed to give a clear response.
Howard and colleagues co-injected synthetic complementary RNA (cRNA) that encodes the
bioluminescent-sensitive protein aequorin and cRNA for the G protein a subunit Gal 1 to
improve the sensitivity of the assay (Howard et al., 1996). With co-injection of Gal 1 cRNA
and aequorin cRNA, human pituitary, rat pituitary and rat hypothalamus poly(A)+ RNA also
gave positive responses to MK-0677, whereas poly(A)+ RNA from control tissues did not
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(Howard et al., 1996). This indicated that a GHS-R, probably coupled to Gall, is present in
human pituitary gland. Using this assay, a swine pituitary cDNA library was screened for an
MK-0677-inducible signal. Stepwise fractionation of a single positive resulted in the isolation
of a single cDNA clone that conferred both MK-0677-evoked aequorin luminescence response
and an inward chloride current in Xenopus oocytes (Howard et ah, 1996).
The nucleotide sequence of the identified clone revealed a full-length swine MK-0677 receptor
cDNA-la, that predicted a protein of 366 amino acids with seven transmembrane (7-TM)-
spanning domains, three intra- and extracellular loops, and a G protein receptor triplet
signature sequence (Howard et ah, 1996). The primary sequence of GHS-R showed that the
receptor was distinct from those of other G-protein-coupled receptors. Genomic analysis by
Southern blotting was consistent with a single highly conserved gene in human, chimpanzee,
bovine, rat, and mouse (McKee et ah, 1997). The GHS-R gene has been localised to human
chromosome 3Q26.2 and mouse chromosome 3a3 (McKee et ah, 1997).
Additionally, cDNA clones that encode a shorter form of the MK-0677 receptor were obtained
(McKee et ah, 1997). This cDNA is called receptor lb cDNA that encodes a polypeptide of
289 amino acids that lacks transmembrane domain 6 and 7 of the la receptor. Unlike the GHS-
R la cDNA, when the lb cDNA is expressed in cells, the resulting protein fails to bind
[35S]MK-0677 and can not be activated by GHS-R ligands (Howard et ah, 1996). The
functional role of this truncated receptor remains to be defined.
1.3.3 Tissue distribution of the GHS-R
Initial in situ hybridisation studies using a cDNA probe selective for GHS-R 1 a to sections of
Rhesus monkey and rat brain indicated that the receptor is expressed in the arcuate nucleus
(Howard et ah, 1996). Localisation of the receptor in this area is consistent with the activation
of Fos protein expression and electrical responses of neuroendocrine arcuate neurones by
GHRP-6 and non-peptidyl GHSs (Dickson et ah, 1995b). However, the precise localisations of
GHS-R mRNA in rat brain were also performed. The mapping study of GHS-R identified its
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expression in pituitary, hypothalamus, hippocampus, substantia nigra, ventral tegmental area,
and dorsal and median raphe nuclei (Guan et al., 1997). The expression of the receptor outside
the hypothalamic area suggests that it might also be involved in mood, cognition, memory or
learning processes. The exact function of expression of the GHS-R gene in areas of the brain
other than those involved in GH release is still unclear. Apart from the pituitary gland, the
receptor was also found to be expressed in the pancreas, but the expression signal was weak
(Guan et al., 1997).
Comparative distribution of mRNA encoding the GHS-R in rat and Microcebus murinus
(Primate, lemurian) showed significant species differences in the periventricular nucleus, the
ventromedial nucleus, the lateral hypothalamic area, and the pituitary gland (Mitchell et al.,
2001), but found consistent expression of GHS-R mRNA in the arcuate and ventromedial
hypothalamic nucleus. These results may indicate the involvement of GHS-R in the control of
GH secretion, feeding behaviour and seasonal rhythmicity among murine species and primates.
Especially in the arcuate nucleus, GHS-R is expressed in NPY neurones (Willesen et al.,
1999), and c-fos mRNA is induced in NPY neurones following GHS administration (Dickson
and Luckman, 1997).
In dwarf rats (dw/dw) with chronic GH deficiency, GHS-R is up-regulated in the arcuate
nucleus, ventromedial hypothalamic nucleus, and in CA1/CA3 regions of hippocampus
(Bennett et al., 1997). Administration of recombinant bovine GH continually for 6 days by
osmotic minipump completely reversed these changes in the arcuate nucleus and ventromedial
hypothalamus, with GHS-R expression falling in both areas to levels significantly below those
in normal rats (Bennett et al., 1997). This study also measured the significantly increased
GHRH concentrations in dwarf rats, which were normalised by GH administration.
GHS-R mRNA of both la and lb were also detected in human pituitary somatotropinomas
removed from patients with acromegaly, and these cultured tumours exhibited strong responses
to GHRP-2 in terms of both phosphatidylinositol hydrolysis and GH secretion (Adams et al.,
1998). Similarly, GHS-R mRNA was also found in normal human pituitary cultures of foetus
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at 18 and 13 weeks of age, and also it has been shown to be functionally responsive to GHS in
vitro (Shimon et al., 1998).
Ong and colleagues developed a photoreactive derivative of hexarelin by inserting a tyrosine
and a Bpa residue (p-benzoyl-L-phenylalanine) for iodination and photolabeling respectively
(Ong et al., 1998). With this technique, they specifically labelled a protein with an apparent
molecular mass of 57000 in human, bovine and porcine anterior pituitary membranes (Ong et
al., 1998). This is an identification of a pituitary GHS-R subtype, which is apparently distinct
from the recently cloned GHS-R.
1.3.4 GHS-R is expressed in GHRH neurones
In situ hybridisation studies using a cDNA probe selective for GHS-R demonstrated that the
receptor is expressed in the arcuate nucleus (Howard et al., 1996). The localisation of
expression in this area of the hypothalamus is consistent with electrophysiology experiments
and Fos protein immunoreactivity. It was hypothesised that GHS-R-expressing neurones were
GHRH-containing arcuate neurones which are neurosecretory. The study using dual
chromogenic and autoradiographic in situ hybridisation showed extensive overlap with GHRH-
expressing neurones in both the arcuate and ventromedial hypothalamic nucleus. In RNase
protection assays, localisations of GHS-R were observed mainly in hypothalamus,
hippocampus and pituitary (Guan et al., 1997). These data showed expression of GHS-R
specifically in many central and peripheral tissues that are generally considered as being
involved in GH release, but also in some regions, including ventromedial hypothalamic
neurones, that seem unlikely to be specifically involved in GH release.
1.3.5 Most GHS-R-containing neurones are NPY neurones
In the arcuate nucleus, 20-25 % of GHRH mRNA-expressing neurones contained GHS-R
mRNA, whereas most of the arcuate GHS-R-mRNA-containing cells did not contain detectable
GHRH mRNA (Willesen et al., 1999). This study found that GHS-R mRNA was expressed in
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94 % of neurones expressing NPY, 8 % of those expressing proopiomelanocortin (POMC) and
30 % of those expressing somatostatin mRNA. It suggests that while part of secretagogue's
effect mediates a direct stimulation of GHRH release, other secretagogue effects are to be
expected. The population of c-fos mRNA-expressing neurones was also studied using in situ
hybridisation. In GHRP-6-injected rats, neurochemically identifiable cells expressing c-fos
mRNA also express NPY (neuropeptide Y) mRNA (51 +/- 4%), GHRH mRNA (23 +/- 1%)
tyrosine hydroxylase mRNA (11 +/- 3%), POMC mRNA (11 +/- 2%), or somatostatin mRNA
(4 +/- 1%) (Dickson and Luckman, 1997).
NPY is abundant in the hypothalamus, but is mainly synthesised in a sub-population of
neurones in the arcuate nucleus (Morris, 1989). The NPY pathway that projects from the
arcuate nucleus to the paraventricular nucleus (PVN) is stimulated under conditions of negative
energy balance (Beck et al., 1990b). Intracerebroventricular injection ofNPY stimulate feeding
and increased immunostaining of Fos in several hypothalamic sites, including the parvocellular
and magnocellular paraventricular nucleus, and these effects on both feeding and Fos induction
were altered by the NPY Y1 receptor antagonist, 1229U91 (Yokosuka et ah, 1999). These data
suggest the involvement of NPY and the paraventricular nucleus in feeding regulation. The
NPY pathways from the arcuate nucleus to the paraventricular nucleus might be involved since
injection of secretagogues to the arcuate nucleus exhibited significant orexigenic effects in rats
(Torsello et ah, 2000). However, only a small proportion of arcuate neurones that project to
paraventricular nucleus are activated by injection of GHRP-6 (Honda et ah, 1999). Thus the
orexigenic effect of this secretagogue may involve other unidentified neural pathways. These
effects are unrelated to actions on GH release. The i.c.v. injection of GHRP-6 significantly
stimulated eating behaviour in a dose-related pattern, but plasma GH concentrations in




Of the many GHSs, GHRP-6 is the most widely used compound, with potent GH releasing
activity both in vitro or when injected intravenously into rats (Bowers et al., 1984). In 1993, a
group from Merck and Co. reported the first non-peptide GHS, L-692429, a mimic of the
GHRP-6 (Smith et al., 1993). Thereafter, an even more potent non-peptide GHS, MK-0677,
was synthesised using GHRP-6 as a template (Patchett et al., 1995).
The possibility that GHSs act via an unknown hypothalamic factor (U factor) is still open. It
was rather unusual that GHSs had been developed, while neither GHS-R nor an endogenous
ligand for this receptor was identified. In 1996, the GHS-R was cloned, and it does not show
sequence homology with other G-protein-coupled receptors known so far (Howard et al.,
1996). This identification ofGHS-R emphasised the existence of a second route of endogenous
factor or hormone that regulates GH release. After the identification, a search for its
endogenous ligand was actively performed, with the use of the 'orphan receptor strategy'.
1.4.1 Purification and identification of ghrelin
Cells expressing an orphan G-protein-coupled receptor have been used to identify unknown
endogenous ligand (for review see Civelli, 1998). The discovery of the GHS-R was a key
factor of searching for its novel ligand. Especially, its binding with synthetic GHSs provided a
convenient positive control for the assay used to identify the endogenous ligand.
Concentrations of intracellular calcium were monitored in order to detect GHS-R stimulation.
Because of the presence of GHS-R in the pituitary and the hypothalamus, a novel ligand was
thought to be produced in the brain. However, tissue extract from rat brain failed to induce
significant changes in intracellular calcium in CHO cell line expressing rat GHS-R (CHO-
GHSR62), whereas the stomach extract did (Kojima et al., 1999). The active peptide was
further purified from the stomach extract by gel filtration, two ion exchange columns and
reverse-phase high-performance liquid chromatography (RP-HPLC). These processes revealed
potent intracellular calcium-increasing activity in the fractions of relative molecular mass of
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approximately 3,000 (Kojima et al., 1999). Active fractions were further purified by HPLC,
followed by RP-HPLC to give pure ghrelin, from ghre, a word root in the Proto-Indo-European
language for grow.
Kojima and colleagues continued to identify ghrelin. Purified rat ghrelin is a 28-amino acid
peptide, and was determined by a protein sequencing to be
GSXFLSPEHQKAQQRKESKKPPAKLQPR in which the third residue X was not identified
(Kojima et al., 1999). An expressed sequence tag clone revealed that the third residue is a
Serine, which was later confirmed in cDNA clones encoding the peptide precursor isolated
from a rat stomach cDNA library. However, the synthetic 28-residue peptide (with X = Ser)
with the sequence deduced from cDNA analysis did not increase intracellular calcium.
Moreover, RP-HPLC showed that purified natural ghrelin had a longer retention time than the
synthetic peptide, which means the natural ghrelin has greater molecular weight. Mass
spectrometric analysis confirmed that the molecular weight of purified ghrelin (3315) was 126
Da greater than the synthetic peptide (3189). This indicates that Ser 3 in natural ghrelin must
be modified by a hydrophobic moiety. Choices of modifications of ghrelin with substances
such as a metal, a carbohydrate or lipid, were discussed, and found not convincing. With
considerations of molecular weight and elution time from RP-HPLC, the modification was
thought to be a hydrophobic compound. Addition of an acyl acid, w-octanoic acid (molecular
mass 144) was the most probable modification. Then, the hydroxyl group of Ser3 of the
synthetic peptide was esterified by n-octanoic acid, the resulting modified peptide was of the
same molecular weight as purified ghrelin. Moreover, the acyl modification increased the
hydrophobicity of the peptide. In the same study, the peptide was then modified at a Ser3 with
/z-octanoic acid, and characterised. The synthetic n-octanoylated peptide needed the same
retention time as the purified ghrelin to elute on RP-HPLC. Mass spectrometric fragmentation
patterns of the synthetic modified peptide and the purified ghrelin were the same. Moreover,
these two peptides had the same effect on the GHS-R-expressing cells. These results confirmed
the success of the ghrelin synthesis.
Studies using radioimmunoassay combined with RP-HPLC revealed two forms of
immunoreactive-ghrelin in rat stomach (Hosoda et al., 2000a). The first form was recognised
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by antisera established against the octanoyl-modified portion, whereas the second form was
recognised by antisera against the C-terminus portion of ghrelin. The first form of ghrelin was
functionally active in increasing intracellular calcium concentration in CHO-GHSR62 cells.
The second form eluted from RP-HPLC at the same retention time as that of synthetic non-
modified ghrelin. These results indicate that non-modified ghrelin also exists in rat stomach
tissue.
In addition, another ligand, des-Gln14-ghrelin, was also purified and characterised as the second
endogenous ligand for GHS-R from rat stomach (Hosoda et ah, 2000b). This form is identical
to ghrelin except for a missing glutamine at the residue 14. Des-Gln14-ghrelin also contains n-
octanoylated serine like ghrelin. It was demonstrated to be produced through an alternative
splicing of rat ghrelin gene (Hosoda et ah, 2000b). When injected into rats, it stimulated GH
release, but the amount of des-Gln14-ghrelin in rat stomach is relatively low compared with that
of ghrelin and des-acyl ghrelin. Thus, w-octanoylated full-length ghrelin and des-acyl ghrelin
are the two major forms of this hormone in rat stomach.
1.4.2 Physiological functions of Ghrelin
In an assay for GH-releasing activity using primary cultured pituitary cells, ghrelin specifically
induced GH release in a clear dose-dependent manner (Kojima et ah, 1999). The induction of
GH release by ghrelin was specific. No other pituitary hormone was affected in vitro. In vivo,
ghrelin when injected intravenously in anaesthetised rats, increased GH to maximum levels at
5-10 min following the injection (Kojima et ah, 1999). Similarly, a single i.c.v. administration
of ghrelin to rats increased the plasma GH concentration in a dose-dependent manner, peaking
15-20 min after administration and returning to basal level after 60 min (Date et ah, 2000b).
However, the GH secretory pattern of adult male rats as shown by episodic bursts was
unaltered following central ghrelin (1 pg/rat) administraion (Kamegai et ah, 2000). No
significant difference from the saline control group was observed in plasma leuteinising
hormone (LH), thyroid stimulating hormone (TSH) or prolactin following a single i.p. injection
of ghrelin at the dose of 30 nM (Wren et ah, 2000). However, ghrelin (2 nM), when injected
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intracerebroventricularly, increased not only GH secretion, but also increased ACTH secretion
and suppressed TSH secretion, and did not alter plasma LH or prolactin (Wren et al., 2000).
1.4.3 The effects of ghrelin on food intake
Intracerebroventricular injection of ghrelin caused a dose-dependent increase in food intake
over 4 h, and ghrelin-induced food intake was significantly inhibited by a NPY antagonist,
BIBO3304 (Lawrence et al., 2002). Significant stimulation of food intake by ghrelin has been
observed at the intraperitoneal dose as low as 1 nM, the dose which yielded plasma ghrelin
concentrations not significantly greater than those measured after a 24-h fast (Wren et al.,
2001). Food intake induced by i.c.v. injection of ghrelin was more effective than GHRP-6, and
was suppressed by an antagonist for GHS-R, [D-Lys-3]-GHRP-6 (Nakazato et al., 2001). Both
starvation-induced feeding and food intake in free-feeding rats were suppressed by anti-ghrelin
immunoglobulin G (Nakazato et al., 2001). These findings indicate that ghrelin is a powerful,
endogenous orexigenic peptide.
A single i.c.v. injection of ghrelin increased in the number of Fos-positive neurones in the
hypothalamic arcuate nucleus, the paraventricular nucleus, the dorsomedial hypothalamus, the
lateral hypothalamus, and the nucleus of the tractus solitarius and the area postrema of the
brainstem (Lawrence et al., 2002). The patterns of Fos induction by ghrelin were similar to
those induced by GHRP-6. GHRP-6 induced the same pattern of Fos immunoreactivity in rats
with free access to food and in rats that had food withheld (Lawrence et al., 2002). Thus, the
activation of these brain regions by GHRP-6 was not secondary to food intake. Ghrelin might
also activate these brain regions independently of food intake, according to its identical sites of
receptor binding and hypothalamic action to those ofGHRP-6. Intranuclear injection of ghrelin
was used to compare the orexigenic response between hypothalamic nuclei. After injection of
30 nM ghrelin into the arcuate nucleus of male rats, food intake was significantly greater than
in rats given ghrelin microinjections into other nuclei (Wren et al., 2001).
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Both repeated i.p. and i.c.v. administration for 7 days increased accumulative food intake with
no detectable attenuation of ghrelin-induced feeding on repeated administration, and increased
in body weight gain (Wren et ah, 2001). Chronic central administration of rat ghrelin (1 pg/rat
every 12 h for 72 h) resulted in a significant increase food intake, but did not affect plasma
insulin, glucose, leptin, or GH concentrations (Kamegai et al., 2001b). This chronic central
administration of ghrelin also increased both NPY mRNA and agouti-related protein (AGRP)
mRNA levels in the arcuate nucleus (Kamegai et al., 2001b). These results indicated that the
primary hypothalamic targets of ghrelin are NPY/AGRP-containing neurones. They are also
consistent with the finding of co-localisation of GHS-R and NPY mRNA in the arcuate of the
rat (Willesen et al., 1999). The involvement of NPY pathway was strongly confirmed when
increased food intake by ghrelin was reversed in a dose-dependent manner by co-injection of J-
115814, a NPY Y1 receptor antagonist (Shintani et al., 2001). These results support the finding
that acute administration of GHRP-6 induced c-fos mRNA in the arcuate neurones that also
contain GHRH mRNA and NPY mRNA (Dickson and Luckman, 1997).
1.4.4 Tissue distribution of ghrelin
High concentration of ghrelin in rat stomach was a key factor that led to the success of ghrelin
purification and identification (Kojima et al., 1999). Since then, in situ hybridisation or
immunohistochemical analyses have investigated the localisation of ghrelin. Ghrelin-
immunoreactive cells were shown to be located in the hypothalamic arcuate nucleus as well as
in the stomach (Kamegai et al., 2000). However, it is not definite whether the detection of
ghrelin in the hypothalamus reflects local production of ghrelin or ghrelin peptide derived from
stomach.
In situ hybridisation also showed the distribution in the rat hypothalamus (Kojima et al., 1999).
Northern blot analysis of human tissues revealed that ghrelin mRNA expression was found
most abundant in the stomach, and followed by the duodenum, jejunum and lung (Ariyasu et
al., 2001). This was correlated to the detection of ghrelin-immunoreactive cells which were
abundant from the neck to the base of the rat oxyntic gland, as well as small numbers of ghrelin
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cells present in upper small intestine and very small numbers present in the lower small
intestine and large intestine (Date et al., 2000a). In rat oxyntic gland, ghrelin was localised on
round, compact, electron-dense granules of ghrelin-producing cells which were approximately
30 nm in diameter, smaller than the granules ofD cells and enterochromaffin-like cells (Date et
al., 2000a). Ghrelin mRNA and peptide were also detected in rat and human pituitary
(Kamegai et al., 2001a). No significant amount of ghrelin mRNA was detected in the
esophagus, ileum, ileocecum, cecum, colon, rectum, liver, brain, heart, skeletal muscle,
thymus, spleen, kidney, placenta, or leukocyte (Ariyasu et al., 2001).
1.4.5 Regulation of ghrelin biosynthesis
In totally gastrectomised patients, plasma ghrelin-like immunoreactivity levels were reduced to
35 % of those in control subjects (Ariyasu et al., 2001). Plasma ghrelin-like immunoreactivity
levels were increased by 31 % after 12-h fasting and reduced by 22 % immediately after
feeding in human (Ariyasu et al., 2001). It can be concluded that the stomach is a major source
of circulating ghrelin and that plasma ghrelin-like immunoreactivity levels reflect feeding
states in human.
Both ghrelin mRNA and peptide were not detectable in stomach extracts of rat foetus until 1
day of age, then increased progressively as a function of age through the second and third
weeks of life (Lee et al., 2002). The increase in levels of ghrelin expression postnatally might
be due to a developmental role of ghrelin to increase food intake and growth after birth.
Ghrelin mRNA expression in the stomach is up-regulated upon fasting and after insulin or
leptin administration (Toshinai et al., 2001). The concentration of ghrelin peptide in the
stomach tissue decreased after fasting and increased after refeeding (Toshinai et al., 2001).
Levels of many neuroendocrine peptides change with age or are influenced by puberty.
However, levels of expression of ghrelin mRNA in stomach of male and female rats were
similar (Gualillo et al., 2001). In addition, gastric ghrelin mRNA content seems to be relatively
stable especially after 40 days of life both in male and female rats (Gualillo et al., 2001). The
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independence of sex steroid influence on ghrelin expression was confirmed by unchanged
levels of the expression in gonadectomised rats following gonadectomy (Gualillo et al., 2001).
In rat pituitary, ghrelin mRNA was up-regulated following infusion of human GHRH
(Kamegai et ah, 2001a). The expression of ghrelin in the pituitary might be part of regulation
ofGH response, whereas the expression in the stomach should be regulation of energy balance.
Since ghrelin and GHSs have been found to have selective site of action in the arcuate nucleus
for regulation of GH secretion and energy balance, the objective of this study was to
investigate the mechanism of GHS in the arcuate nucleus. To understand how GH secretion is
associated with feeding control, interaction between GHS and NPY in the arcuate nucleus was
needed to be examined for more clarification. In addition, the ventromedial hypothalamic
nucleus has been found to be most sensitive to change of energy balance. Thus, study of effects
of these compounds also in this area could be able to explain mechanism ofGHS clearer.
CHAPTER 2
IN VITRO ACTION OF GH SECRETAGOGUES ON





Growth hormone-releasing peptide-6 (GHRP-6) is one of the earliest compounds that was
recognised as a selective and potent growth hormone secretagogue, and its effects are the most
well-documented among synthetic secretagogues. Its effects on GH release was confirmed not
to be via the same pathway as the endogenous GHRH when a combination of GHRP-6 and
GHRH synergistically induced greater release of growth hormone than either treatment alone
(Bowers et al., 1984).
Direct evidence that the arcuate nucleus is a site of action ofGH secretagogues came first from
electrophysiological studies of arcuate neurones. Intravenous injection of GHRP-6 elicited
electrical activation of arcuate neurones that were antidromically identified as projecting to the
median eminence (Dickson et al., 1995b). Evidence that these effects were specific to the
arcuate nucleus came from studies of Fos expression, which showed that, in the hypothalamus,
the only region in which GHRP-6 evoked significant Fos expression was the arcuate nucleus.
Within the arcuate nucleus, it emerged from subsequent studies that GHRP-6 (and other
synthetic secretagogues) induced the same localised pattern of Fos expression whether given
systemically or by i.c.v. injection, indicating that the localised nature of Fos expression does
not reflect limited penetration of secretagogues into the brain. By contrast with GHRP-6,
neither GHRH, nor IGF-1, nor GH itself induced Fos expression in the arcuate nucleus,
indicating that the response to GHRP-6 was not secondary to stimulation ofGH release.
Identification by double immunohistochemistry (Dickson et al., 1996) or double in-situ
hybridisation (Dickson and Luckman, 1997) established that, within the arcuate nucleus,
GHRP-6 activated a high proportion of neurones that expressed GHRH, but activated a very
low proportion of neurones that expressed TH-containing, P-endorphin, somatostatin or
POMC. However most of the cells activated by GHRP-6 in the arcuate nucleus did not express
detectable GHRH mRNA, but do apparently express NPY. This conclusion was supported by
recent studies showing co-localisation of growth hormone secretagogue receptors in NPY
neurones in the arcuate nucleus (Willesen et al., 1999).
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The functional identity of the neurones activated by GHRP-6 in the arcuate nucleus though has
remained unclear. Certainly as expected, GHRH neurones are activated. The Fos expression
that is induced by GHRP-6 is attenuated by a central action of somatostatin, as is secretagogue
(MK-0677)-induced excitation of arcuate neurones (Bailey et al., 1998), again indicating a
functional association of secretagogue effects with regulation of growth hormone secretion.
Somatostatin may therefore be a functional antagonist of GHRP-6 or other secretagogues that
act centrally. However not all secretagogue-responsive neurones are inhibited by somatostatin,
so is there another functionally independent population in the arcuate nucleus that is activated
by secretagogues, and if so, what might its functional role be?
Whether the activation of NPY-expressing neurones in the arcuate nucleus is functionally
associated with the effects of secretagogues on GH secretion or is part of an independent
physiological response is unclear. NPY is expressed in many different cell populations, so the
presence of NPY in activated cells is not a definitive indication of functional identity. An
important population ofNPY cells in the arcuate nucleus is believed to have a major role in the
regulation of food intake, and there have been reports that a sub-population of neurones in the
arcuate nucleus which contain NPY are glucose sensitive (Muroya et al., 1999). The role of
NPY has been extensively studied both in the control of normal food intake and also in studies
of eating disorders; for example, the concentration of NPY in the arcuate nucleus of the
hyperphagic obese Zucker rats is much greater than in the lean normophagic rats (Beck et al.,
1990a). The effects of NPY on food intake are believed to be exerted principally by a direct
projection from NPY cells in the arcuate nucleus to the paraventricular nucleus. However NPY
expression may not be confined to this cell population, even within the arcuate nucleus.
Electrophysiological studies, and studies involving co-localisation of Fos expression with
fluorogold administered systemically showed that the majority of cells in the arcuate that
express Fos in response to secretagogues appear to be neurosecretory neurones, in that they
project outside the blood-brain barrier (Dickson et al., 1996). However, electrophysiological
studies in vivo indicate that arcuate neurones that project to the paraventricular nucleus are not
neurosecretory. They do not also project to the median eminence (Honda et al., 1999), and
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studies of Fos expression in arcuate neurones identified by retrograde tracing as projecting to
the paraventricular nucleus indicate that very few of these neurones are activated by GHRP-6.
Thus it appears that GHRP-6 activates a population of NPY containing cells in the arcuate
nucleus, but these appear to be neurosecretory cells rather than the cells that project to the
paraventricular nucleus and regulate food intake. In addition, the paraventricular nucleus is
probably not the only site of action ofNPY in mediating its effects on feeding. In a behavioural
study, microinjection of a unique carboxy terminal fragment of NPY into the ventromedial
hypothalamus caused significant reduction of eating response induced by NPY (Myers et al.,
1995).
Given the specific localisation of GHRP-induced Fos expression to the arcuate nucleus, it was
surprising therefore that, when the GHS receptor was cloned and its distribution in the brain
mapped, receptor expression was not confined to the arcuate nucleus, but was also prominent
in the ventromedial nucleus of the hypothalamus (Bennett et al., 1997). Additionally,
extracellular recordings showed the increase in firing rate of ventromedial hypothalamic
neurones following bath application of GHRP-6 to hypothalamic brain slices (Hewson et al.,
1999). This study used very high concentrations of secretagogue, leaving open the question of
whether the arcuate and ventromedial hypothalamus differ in their sensitivity to secretagogues.
GHRP-6 was selected for this in vitro study. Due to its potency and selective action in the
hypothalamus, it is the most predominant GHS that has been previously used to study
mechanism of GH secretion. In this study, L-144,446, the newly synthesised secretagogue was
also used for the in vitro study in comparison to GHRP-6.
2.2 Aims
As both the arcuate and the ventromedial hypothalamic nucleus mediate effects of GH
secretagogues and NPY in vivo, this study aimed to investigate the effects of the secretagogue
L-144,446, the newly synthesised non-peptidyl compound and GHRP-6 on both brain regions
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at the single cell level by using hypothalamic brain slices for extracellular recording. The aim
was also to examine whether neurones in these regions respond to somatostatin, NPY and
changes in glucose concentrations.
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2.3 Methods and materials
2.3.1 Preparation of tissue slices for electrophysiological recording
Male Sprague Dawley rats (200-350 g) were housed and maintained in a controlled
environment with 12:12 h dark:light cycle. Water and food pellets were supplied ad libitum.
All animal experiments in this chapter and the rest of this study were undertaken in full
accordance with Home Office requirements for licensing of animal experiments. Rats were
decapitated and their brains were quickly removed from skulls. Subsequent dissection was
performed at a temperature of 4°C. Rat brains, on ice, were coronally cut by a razor blade
through the areas of the optic chiasm and the midbrain to obtain brain chunks containing the
whole range of the hypothalamus. These brain chunks were then trimmed with a scalpel blade
to remove extra-hypothalamic areas, and the areas that contained the arcuate nucleus and
ventromedial hypothalamus were retained. A piece of trimmed rat brain was fixed onto the
cold plastic stage with the median eminence side facing the vibratome blade. The stage
containing the brain chunk was then fixed into vibratome chamber and submerged under
chilled artificial cerebrospinal fluid (aCSF, see solution preparation) which was oxygenated
with a mixture of 95% O2 and 5% CO2. Using a vibratome (Campden Instruments Ltd, UK),
the hypothalamic brain chunk was coronally cut into three slices with a thickness of 400 pm.
Each slice was finally divided in half symmetrically through the third ventricle. To mark the
location of the recording area, two marks on the wall of the third ventricle of each slice were
made by using a scalpel blade as shown in fig. 2.1. Then slices were maintained in oxygenated
aCSF at room temperature for the extracellular recording. The slice preparation starting from
decapitating the brain until cutting with Vibratome was completed in no longer than 5 min.
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Fig. 2.1. (A) Rat brain atlas (Bregma -2.56 mm, Paxinos and Watson, 1996) used
for confirmation of the hypothalamic brain areas for extracellular recording.
(B) Schematic diagram showing the regions of the arcuate nucleus and the
ventromedial hypothalamic nucleus. The hypothalamic brain slice was divided
into two halves bilaterally. Two marks (smallcuts made with a scalpel blade) were
made on the wall of the third ventricle, to divide it into one-third parts. These marks
were used to guide the placement ofmicroelectrode for recording as indicated in (B).
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A coronal section containing the arcuate nucleus and ventromedial hypothalamic nucleus was
then placed in an interface recording chamber. It was continuously perfused with oxygenated
aCSF fluid at 1.5 ml/min using a peristaltic pump (Gilson, France). The temperature and
humidity of the recording chamber were maintained by adjusting an automatic temperature
controller (Warner Instrument Corp, USA) to 33°C and supplying with a continuous stream of
a mixture of 95% O2 and 5% CO2. Each slice was incubated for at least 1 h in the gas-liquid
interface chamber before starting recording.
2.3.2 Recording extracellular activity
Microelectrodes were made from Borosilicate glass capillaries (Harvard Apparatus Ltd, UK).
Flaming-Brown micropipette puller (Sutter Instrument Corp, USA) was used to pull glass
capillaries into microelectrodes with the desired resistance (10-20 MQ). Microelectrodes were
filled with aCSF and then fixed to the amplifier headstage. They were placed visually under the
light microscope within either the arcuate nucleus or ventromedial hypothalamic nucleus to
enable extracellular single-unit recordings to be made. Tonically firing neurons in both areas
were randomly explored. Single-unit activity was amplified, through an Axoclamp 2B
amplifier (Axon Instruments, USA). It was filtered and monitored with an oscilloscope and
audio amplifier.
Arcuate and ventromedial hypothalamic neurones were identified with guidance from a
previous study of their characterised electrophysiological properties (Dickson et al., 1995b;
Roesch and Felix, 1984). The spontaneous discharge rate of active neurones was displayed and
converted online using a 1401 (analog-to-digital) interface (CED, Cambridge, UK). A height
window discriminator (Gould Electronics Ltd, UK) was used to discriminate proper action
potential from background level. Signal was then transferred to a PC running Spike 2 software
(CED, Cambridge, UK) for analysis and interpretation.
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2.3.3 Chemicals
Data collection was commenced after recording a stable period of neuronal baseline activity for
at least 15 min. Brain slices were tested with various types of drug which included growth
hormone secretagogue (GHS) 144,446 (Merck, UK), growth hormone releasing peptide-6
(GHRP-6, Merck, UK), somatostatin (Sigma, USA), neuropeptide Y (Tocris Cookson Ltd,
UK), or NPY Y1 antagonist (L-753044-001J003: Merck, UK). All drugs and antagonist were
dissolved in ddH20, divided into aliquot parts and frozen until required. Aliquots were diluted
to their final concentrations in the appropriate volume of oxygenated aCSF and applied to the
slice by switching the perfusion inlet tube to the desired solution by means of three way taps.
In experiments using various concentrations of glucose, the osmolality of the medium was kept
constant by compensatory changes in NaCl (Yang et al., 1999). As well as in the experiment
with Ca"1-1" removal, the osmolality was also maintained by compensation with MgS04 (Kelso
and Boulant, 1982). Each brain slice was used for only one recording in order to avoid
prolonged sustaining effect ofGHS.
2.3.4 Solution preparation
2.3.4.1 Artificial cerebrospinal fluid (aCSF)
Concentrations and amounts of chemicals
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Low calcium aCSF
Final concentration (mM) amount per 1000 (g)
125 Sodium chloride 7.305
5 Potassium chloride 0.373
1.25 Potassium dihydrogen 0.170
orthophosphate
0.25 Calcium chloride 0.0734
1.1 Magnesium chloride 0.102
3.63 Magnesium sulphate 0.893
26 Sodium bicarbonate 2.16
10 Glucose 1.8
2.3.4.2 aCSF with various concentrations of glucose
Chemicals
Final conc. (mM)/amount of chemicals (g) for 1000 ml aCSF
20 mM glucose 5 mM glucose 0 mM glucose
Sodium chloride 120/7.61 127.5/7.45 130/7.60




Calcium chloride 2.5 /0.367 2.5 /0.367 2.5 /0.367
Magnesium sulphate 1.25/0.308 1.25/0.308 1.25/0.308
Sodium bicarbonate 26/2.16 26/2.16 26/2.16
Glucose 20/3.64 5/0.91 0/0
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Results
2.3.5 Electrophysiological studies of arcuate neurones
2.3.5.1 Basal activity and activity patterns of arcuate neurones
Stable extracellular recordings were made from 107 spontaneously active neurones in the
ventromedial region of the arcuate nucleus of the trimmed rat hypothalamic slice preparation.
Each neurone was recorded from a different slice, and was tested with application of
secretagogue alone or in combination with other dmgs.
All recorded neurones discharged with no conspicuous pattern - in particular no neurones fired
phasically, in the manner of vasopressin neurones of the supraoptic (Armstrong and Sladek,
1982) and paraventricular nuclei (Saphier, 1991), and no neurones fired very regularly, in the
manner of many neurones in the suprachiasmatic nucleus (Glotzbach et al., 1987). The mean
variation coefficient was 112 + 4.8 %, which confirms their highly irregular firing pattern. The
mean spontaneous firing rate of these arcuate neurones was 1.13 ± 0.08 spikes/s (mean ± SEM)
ranging from 0.22 to 4.51 spikes/s. The discharge patterns of these neurones were also studied
by analysing the distributions of interspike intervals. The interspike interval distribution of a
neurone is influenced by intrinsic neuronal properties, such as the presence of a post-spike after
hyperpolarisation or an after-depolarisation, and hence these can be useful in classifying
neurones into different functional types. For the neurones analysed, most of them (92 %) had a
predominant (modal) interspike interval. The average modal interspike interval in the control
period was 0.43 ± 0.04 s, and 16 neurones (15 %) showed a modal interspike interval of less
than 100 ms. Of the remainder, 91 neurones (85 %) showed a more dispersed interspike
interval histogram with a modal interspike interval greater than 100 ms. Firing patterns with bi-
modal interspike interval distributions were also seen in 8 neurones (8 %). The mean firing
rates and interspike intervals of neurones that responded and did not respond to secretagogues
will be shown in parts of the results of the effects of secretagogues on arcuate neurones.
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2.3.5.2 Response of arcuate neurones following administration of L-144,446
Responses to L-144,446 were examined in recordings from 38 arcuate neurones. The response
of each neurone to L-144,446 was determined by comparing its mean firing rates in a control
period (measured over 10 min immediately before drug administration), and after exposure to
L-144,446 (measured from 5 to 15 min following the treatment). This period was selected as
including the maximum differences from the control period shown in the average response of
all cells before classification. The minute-by minute firing rates in these two periods were
compared statistically using Students t-test. Two initial arcuate neurones that were stimulated
by two different concentrations of L-144,446 are shown in fig. 2.1.1. Figure 2.1.1A shows a
neurone stimulated by L-144,446 (10~7 M) for 5 min that increased its firing rate from 1.11
spikes/s to 5.91 spikes/s, more than a 5-fold increase (fig. 2.1.1A). Figure 2.1.IB shows a
different neurone stimulated by a lower concentration of L-144,446 (10~8 M) for only 2 min,
showing an increase in firing rate from 1.99 spikes/s to 4.15 spikes/s, approximately a 2-fold
increase (fig. 2.1.1B). After such pilot experiments, the concentration of 10"8 M for 2 min was
selected to be the condition of the rest of the study of L-144,446. This dose was selected as the
lowest dose that would consistently produce clear effects on arcuate neurones.
The effects of L-144,446 were examined on 38 arcuate neurones. To classify neurones as
excited, inhibited, or non-responsive, the data for each cell were first normalised by subtracting
the mean firing rate in the control value from each minute-by-minute value of firing rate. Mean
change in firing rate of each neurone tested were plotted in order of magnitude (fig. 2.1.2 A).
The population was divided into three groups. Four of the tested neurones (11 %) were
significantly inhibited by L-144,446 (P < 0.02). The average firing rate of this group decreased
by 0.52 spikes/s (24 %; from 2.16 ± 1.09 to 1.64 ± 0.85 spikes/s). Fourteen neurones (37 %)
did not show any significant change following administration of L-144,446 (P = 0.02). Twenty
neurones (53 %) showed a significant (95 %) increase in firing rate after L-144,446
administration (P< 0.008). The average firing rate of this group increased from 0.97 ±0.17 to


























Fig. 2.1.1. Extracellular recordings of the firing rate of arcuate neurones following
perfusion of the hypothalamic slices with L-144,446. (A) A neurone was stimulated
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with 10 M L-144,446 for 5 min. (B) Another arcuate neurone was stimulated with 10
M LI44,446 for 2 min. The firing rate was divided into 10-s intervals and is expressed as
spikes/s. In each case, the firing rate during the 10-min period taken 5 to 15 min following
secretagogue administration (averaged for 60x10-s intervals) was significantly different
from the firing rate of control period taken 10 min before administration (averaged for






















































Fig. 2.1.2. (A) Ranking of changes in firing rate of39 arcuate neurones following
L144,446 treatment. Mean firing rate of each individual neurone during the 10-min
period after the secretagogue application (10~8 M, 2 min) was normalised by
subtracting the mean firing rate of the control period (10-min period before the
application). Neurones were divided into 3 groups according to their responses.
Changes in firing rate after LI44,446 treatment were statistically significant in the
inhibited group (t-test, p< 0.02) and excited group ( p< 0.0075) but not in the non-
responsive group. Each bar represents the change in firing rate (± SEM) of one
individual neurone following secretagogue administration. (B) Mean response of the
excited group following L-144,446 treatment. Normalised mean firing rates of the
excited neuroneswere averagedminute-by-minute (n = 5 -18 per each point).
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The basal firing patterns of these three classified groups of the arcuate neurones were then
compared. The modal interspike interval of the discharge was taken as the peak in interspike
interval histogram of the 10-min period of recording before administration of L-144,446. The
modal interspike interval of neurones from these 3 groups was then plotted against mean
interspike interval (fig. 2.1.3). The excited neurones had mean firing rates which varied
between 0.23 and 2.55 spikes/s with a mean ± SEM of 0.97 ±0.17 spikes/s. Seventeen of a
total 20 excited neurones had uni-modal interspike interval with an average mode of 0.36 ±
0.13 s, whereas the remaining 3 of excited neurones had bi-modal interspike interval
distributions. Non-responsive neurones had a mean firing rate of 1.03 ± 0.23 spikes/s and an
average modal interspike interval (averaged from 13 neurones with uni-modal interspike
interval of a total 14) of 0.18 ± 0.03 s. Four of the inhibited neurones were found to have wide
range of mean firing rate, from 0.34 to 4.51 spikes/s with a mean firing rate of 2.07 ± 1.14
spikes/s and an average modal interspike interval of 0.88 ± 0.52 s. It was noticed that all 9
neurones with modal interspike intervals higher than 0.35 s were responsive to L-144,446; 2
were inhibited and 7 were excited. However, the majority of excited and non-responsive
neurones had a modal interspike interval of less than 0.5 s and firing rate of lower than 2 s.
These two groups of neurones are not simply distinguishable by this analysis.
Further analysis revealed that the inhibited and excited groups had non-significant higher
regularity in firing patterns than the non-responsive group (t-test, p = 0.05). The variation
coefficients of the inhibited and excited groups were 130 ± 24 % and 134 ± 9 % respectively
whereas the variation coefficient of the non-responsive group was 158 ± 18 %. The shorter
average modal interspike interval in the non-responsive cells may reflect an observation made
previously from in vivo recordings. Dickson and co-workers (Dickson et al., 1995b) reported
that some arcuate neurones in vivo fire in clusters of action potentials; these cells display an















Modal interspike interval (s)
Fig. 2.1.3. Relationship between mean and modal of interspike interval of basal
firing activity of arcuate neurones treatedwith L144,446. Neurones were divided
-8into 3 groups according to their responses to L-144,446 (10" M, 2-min bath
application). For each cell, mean and modal interspike intervals were analysed from its
control period (10min before the treatment).
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The mean increase in firing rates of excited neurones were averaged and plotted (fig. 2.1.2B).
The increase was clearly seen to begin a few minutes after the administration of L-144,446 -
during the period of drug washout. The response thereafter increased progressively, to reach a
peak approximately 1 spikes/s higher than the initial control level at about 20 min. The mean
firing rate remained elevated above control levels for about 50 min after the administration.
The firing patterns of some arcuate neurones changed following exposure to L-144,446. Of 20
neurones that were excited by L-144,446, 15 neurones (75 %) showed an increase in regularity
of their firing pattern. Two representative L-144,446-stimulated neurones showed changes of
variation coefficient following the excitation compared to variation coefficient of control
period (fig. 2.1.4 and 2.1.5). However, the overall decrease in variation coefficient of these L-
144,446-stimulated neurones was not statistically significant (t-test, P = 0.05).
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Fig. 2.1.4. Effects of L144,446 on regularity of discharge pattern of a
representative arcuate neurone. Upper panel illustrates the ISI histogram compiled
before (left) and after (right) bath application (2 min) of L-144,446 (108 M). The
decrease in variation coefficient reflects an increase in regularity of its discharge
pattern after L-144,446 treatment. Lower panel illustrates the effects ofL-144,446 on
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Fig. 2.1.5. Effects of L-144,446 on regularity of discharge pattern of a
representative arcuate neurone. Upper panel illustrates the ISI histogram
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compiled before (left) and after (right) bath application (2 min) ofL-144,446 (10
M). The increase in variation coefficient reflects a decrease in regularity of its
discharge pattern after L-144,446 treatment. Lower panel illustrates the effects of
L-144,446 on the firing rate of this neurone. Two bars indicate the periods of
control and L-144,446 treatment ISI histograms.
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2.3.5.3 Effects of GHRP-6 on arcuate neurones
The responses to GHRP-6 were examined in recordings from 47 arcuate neurones. Neurones
were classified as excited, inhibited, or non-responsive in the same way as for the effects of L-
144, 446. Figure 2.1.6 shows the mean change in firing rate in response to GHRP-6 of each
neurone tested, plotted in order of magnitude. The figure also shows the mean change in firing
rate due to NPY treatment of some neurones tested with GHRP-6. Effects of NPY will be
shown later in this chapter. The population was divided into three groups. Eight of the tested
neurones (15 %) were, by this test, significantly inhibited by the secretagogue. The average
firing rate of this group decreased by 0.82 spikes/s (36 %, from 0.98 ± 0.20 spikes/s to 0.63 ±
0.17 spikes/s). Twenty-one neurones (45 %) did not show any significant change following
administration of GHRP-6 (P = 0.03). Eighteen neurones (38 %) showed a significant increase
in firing rate following GHRP-6 (P< 0.03). The average firing rate of this group increased by
145 %, from 0.84 ± 0.10 spikes/s to 2.05 ± 0.32 spikes/s.
The basal firing patterns of these three classified groups of the arcuate neurones tested with
GHRP-6 were then compared. The modal interspike interval of the discharge was taken as the
peak in interspike interval histogram of the 10-min period of recording before administration of
the secretagogue. The modal interspike interval of neurones from these 3 groups was then
plotted against mean firing rate (fig. 2.1.7). The excited neurones had mean firing rates which
varied between 0.25 and 2.06 spikes/s with a mean ± SEM of 0.85 ±0.10 spikes/s. Most of the
excited neurones had a uni-modal interspike interval distribution with an average mode of 0.46
±0.11 s (excluding one neurone which had a bi-modal interspike interval distribution). Non-
responsive neurones had a mean firing rate of 0.92 ±0.10 spikes/s ranging from 0.22 to 1.89
spikes/s, and an average modal interspike interval (averaged from 14 neurones with uni-modal
interspike interval histograms) of 0.52 ± 0.12 s. The eight inhibited neurones showed a wide
range of mean firing rate, from 0.22 to 1.60 spikes/s with a mean firing rate of 0.98 ± 0.20












Fig. 2.1.6 . Ranking of changes in firing rate (mean ± SD) of 47 arcuate
neurones following GHRP-6. Mean firing rate ofeach individual neurone during
-7
the 10-min period after the GHRP-6 application (10 M, 2min) was normalised by
subtracting the mean firing rate of the control period (10-min period before the
administration). Neurones were divided into 3 groups according to their responses.
Changes in firing rate due to GHRP-6 treatment were statistically significant in the
inhibited group (t-test, p< 0.001) and in the excited group (p< 0.005), but not in the
non-responsive group. Each bar represents the change in firing rate of one
individual neurone following GHRP-6 treatment. Some non-responsive and excited
neurones were also tested with NPY (10"6 M) in the same recording. Responses to
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Fig. 2.1.7 .Relationship between mean and modal interspike interval
of basal firing activity of arcuate neurones treated with GHRP-6.
Neurones were divided into 3 groups according to their responses to the
-7
GHRP-6 (10 M, 2-min bath application). For each cell, mean and modal
interspike intervals were analysed from its control period (10 min before
the treatment).
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The relationship between modal interspike interval and mean firing rate of neurones tested with
GHRP-6 reveals some characteristics of excited and inhibited groups. The excited group was
found to be clustered in a range of modal interspike interval from 0.5 to 1.5 s. Most of them
(14 from a total of 18) had a mean firing rate less than 1 spikes/s. All of the inhibited group
had a modal interspike interval of less than 1 s. This inhibited group might be distinguished
from those excited group, in that most of the inhibited neurones had mean firing rates higher
than 1 spikes/s, whereas most of the excited neurones had a firing rate lower than 1 spike/s.
In addition, the analysis revealed that the excited group had non-significantly higher regularity
in firing patterns than the non-responsive and inhibited groups (t-test, p = 0.05). Between these
three groups, no significant difference in regularity in firing patterns was determined. The
variation coefficients of the excited, non-responsive and inhibited groups were 115 %, 88 %
and 83 % respectively.
The increase in firing rate of excited neurones stimulated by GHRP-6 (10~7 M) were seen in
various patterns. Recordings of three representative arcuate neurones stimulated by GHRP-6
are shown in fig. 2.1.8. The mean increase in firing rates of excited neurones were averaged
and plotted (fig. 2.1.9). The increase clearly began a few minutes after the administration of
GHRP-6, during the period of drug washout. The response increased steeply, and seemed
stable after reaching a peak in about 15 min, at a mean firing rate approximately 1.2 spikes/s
higher than the initial control level. The mean firing rate maintained elevated above control
levels for about 60 min after the administration.
Inhibitory effects of GHRP-6 were also observed for some arcuate neurones, and three arcuate
neurones that were inhibited by GHRP-6 are illustrated in fig. 2.1.10. The mean firing rates of
inhibited neurones are plotted in fig 2.1.9. The decrease started a few minutes after the
administration of GHRP-6 and peaked in 10 min, at a mean firing rate about 0.5 spike/s lower
than control levels. Thereafter, the mean firing rate gradually increased towards control levels.
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Fig. 2.1.8 . Rate-meter records showing GHRP-6 activation of arcuate
nucleus neurones. Hypothalamic brain slices were superfusated with GHRP-
-7
6 (10 M) for 2 min. The patterns of increase in firing rate varied among
different GHRP-6-excited neurones. The stimulations were maintained for

























































Fig. 2.1.9. Mean responses (mean ± SEM spikes/s) of arcuate neurones that
were excited (A) and inhibited (B) following GHRP-6 treatment. Arcuate
neurones were divided into groups according to their responses to GHRP-6 (see
fig. 2.1.6). In each group, mean firing rate of each individual neurone during the
10-min period after the GHRP-6 application (10"7 M, 2 min) was normalised by
subtracting the mean firing rate of the control period (10-min period before the
administration). Normalised mean firing rates ofneurones were averaged minute-
by-minute for both excited group (n = 7-18 per each point) and inhibited group (n
= 6-8 per each point).
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Fig. 2.1.10. Rate-meter records showing inhibitory effects of GHRP-6 on
arcuate neurones. Hypothalamic brain slices were superfusated with
GHRP-6 (10"7 M) for 2 min. The inhibitions in firing rate were significant (t-
test, p<0.001). Periods ofGHRP-6 treatments are indicated with bars.
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GHRP-6 also changed the firing patterns of some arcuate neurones. Of 18 neurones that were
excited by GHRP-6, 14 neurones (78 %) showed an increase in regularity of their firing
pattern, while 4 neurones (22 %) showed a decrease in regularity of their firing pattern. Two
representative GHRP-6-stimulated neurones showed effects of GHRP-6 on variation
coefficient of their discharge patterns (fig. 2.1.11 and 2.1.12). The average variation
coefficient of the GHRP-6-stimulated neurones reduced by 22 % from 113 ± 11% to 90 ±10
%. However, the overall decrease in variation coefficient of these GHRP-6-stimulated group
was not statistically significant (t-test, P = 0.05).
Comparison of responsiveness to GHRP-6 and L-l44,446
The analysis of discharge patterns of L-l44,446- and GHRP-6-stimulated arcuate neurones
revealed close similarities. The proportions of arcuate neurones that were stimulated by both
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Fig. 2.1.11. Effects of GHRP-6 on regularity of discharge pattern of a
representative arcuate neurone. Upper panel illustrates the ISI histogram compiled
before (left) and after (right) bath application (2 min) of GHRP-6 (10 7 M). The
decrease in variation coefficient reflects an increase in regularity of its discharge
pattern after GHRP-6. Lower panel illustrates the effects of the GHRP-6 on the firing
















Fig. 2.1.12. Effects of GHRP-6 on regularity of the discharge patterns of a
representative arcuate neurone. Upper panel illustrates the ISI histogram
compiled before (left) and after (right) bath application (2 min) of GHRP-6 (10~7M).
The stable variation coefficient reflects no change in regularity of its discharge
pattern after GHRP-6. Lower panel illustrates the effects of GHRP-6 on the firing
rate of this neurone. Two bars indicate the periods ofcontrol and GHRP-6 treatment
ISI histograms.
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2.3.5.4 Effects of calcium removal on L-144,446 excitation in arcuate neurones
The dependence of the excitatory effects of L-144,446 on external calcium were examined in
recordings of 30 arcuate neurones. Recordings started with perfusion of normal medium which
contains 2.5 mM CaCL in order to detect basal firing activity. Thereafter, the perfusate was
switched to the modified medium with remaining 10 % Ca++ (see materials of the chapter 2
for preparation of medium with reduced concentration of Ca++). In these experiments, removal
of external calcium resulted in a large increase in the electrical activity of the recorded
neurones, and these cells were not tested further (fig. 2.1.13A). Twelve cells however showed a
reduction in electrical activity to a low stable level. These cells were then tested, in the absence
of external calcium, with exposure to L-144,446.
Of the 12 arcuate neurones tested under calcium removal condition, 5 neurones (42 %) were
excited by L-144,446. In all of the 5 responsive cells, L-144,446 changed the firing pattern to
be more irregular, with a multiple spike bursting pattern. A representative arcuate neurone
which showed excitatory effect of L-144,446 during perfusion of Ca^-free medium is shown
in fig. 2.1.13B. Patterns of excitation were various among different neurones with different
durations and response rates. Thus, the 10-min period of peak of activation of each neurones
were analysed. At the peak of the responses, the mean firing rate of these 5 cells was elevated
from 0 to 5.33 ± 1.5 spikes/s. At peak period, regularity markedly decreased with variation
coefficient up to 356 %, whereas, in control medium, regularity increased with variation























Fig. 2.1.13. (A) Effects of external calcium removal on electrical activity of the
arcuate neurone. A neurone showed a large increase in firing activity after
perfusate was switched to lower Ca++ concentration medium. The perfusate Ca^
concentration was reduced to 10% of that in normal medium by replacingwithMgT
(B) Calcium-independent effect of L144,446 on electrical activity of the arcuate
neurone. L-144,446 was applied after firing rate of the arcuate neurone was
suppressed by the perfusion of low calcium medium. The periods of low calcium
medium perfusion andL-144,446 application are indicated with bars.
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Of the cells that did not respond to L-144,446, 4 cells were tested a second time with L-
144,446 after return to normal medium. Three of these four cells failed to show any significant
change in firing rate within 10 min after the exposure to the L-144,446 (fig. 2.1.14A), but the
fourth cell showed a strong response (fig. 2.1.14B )
Thus at least some arcuate neurones respond to direct administration of L-144,446 in the
absence of external calcium, indicating that this response is not dependent either upon
calcium entry into the cells, or upon synaptic input arising from neurones in the slice but
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Fig.2.1.14. Dependence on external Ca++ of the effects of L-144,446 on the
electrical activity of arcuate neurones. Each arcuate neurone was challenged
twice with L-144,446 (10~8 M, 2-min bath application); the first time during low
Ca' -medium perfusion and the second time during perfusionwith normal medium.
(A) L-144,446 failed to excitate the arcuate neurone during low Ca++-medium
perfusion but exhibited a rapid excitation when applied during normal medium
perfusion. (B) In another arcuate neurone in which electrical activity was also
suppressed by low Ca++-medium perfusion, the L-144,446 treatment did not exhibit
an excitatory effect either during low Ca++ or normal Ca^-medium perfusion periods.
The periods of low Ca++- medium perfusion and L-144,446 application are indicated
with bars.
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2.3.5.5 Effects of NPY on arcuate neurones
The effects of NPY on arcuate neurones were tested in extracellular recordings from 38
neurones. Initially, 16 arcuate neurones were tested with NPY at 10"7 M for 2 min. The
response of each neurone to NPY administration was determined by comparison between its
mean firing rates in a control period (measured over 10 min before drug administration), and
after exposure to NPY (measured from 2 to 12 min following the treatment). The minute-by
minute firing rates in these two periods were compared statistically.
Five neurones (31.25 %) showed brief but significant inhibitory effects of NPY (data not
shown). In these neurones, a slight decrease was rapidly seen, and inhibition was maximal at
15 min after the administration of NPY. The mean firing rate was reduced by approximately
0.5 spikes/s at the peak of inhibition.
Thereafter, the test concentration of NPY was increased to 10"6 M, keeping the perfusion
period at 2 min. Twenty-two neurones were tested with NPY (10"6 M). Ranking of change in
firing rate is shown in fig. 2.1.15A. Ten neurones (45 %) showed a significant inhibition in
response to NPY (P< 0.03). The mean firing rates of inhibited neurones were plotted (fig.
2.1.15B). The mean firing rate decreased markedly as soon as the peptide reached the brain
slice. Inhibition was maximal approximately 5 min after NPY administration. The mean firing
rate of inhibited neurones, in the period from 2 to 12 min after exposure to NPY, was reduced
by 0.70 spikes/s (35 %; from 1.99 ± 0.38 to 1.28 ± 0.34 spikes/s).
Fifteen arcuate neurones that were stimulated by GHRP-6 were also tested with NPY. Of these
15 neurones, 6 (40 %) were inhibited by NPY, 2 (13 %) were stimulated, and 8 (53 %) were
non-responsive. Three representative GHRP-6-stimulated arcuate neurones that were inhibited
by NPY are shown in fig. 2.1.16,
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Fig. 2.1.15. (A) Ranking of changes in firing rate of 22 arcuate neurones following
NPY treatment. Mean firing rate of each individual neurone during the 10-min period
after the NPY application (10"6 M, 2 min) was normalised by subtracting the mean firing
rate of control period (10-min period before the administration). Neurones were divided
into 3 groups according to their responses. Changes in firing rate (± SEM spikes/s) after
NPY treatment were statistically significant in the inhibited group and excited group (t-
test, p< 0.03), but not in the non-responsive group. Each bar represents the change in firing
rate of one individual neurone following NPY administration. (B) Mean response of the
inhibited group following NPY treatment. Normalised mean firing rates of neurones
6 7inhibited by NPY at concentration either 10" M or10" M were averaged minute-by-
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Fig. 2.1.16. Electrophysiological responses of GHRP-6-excited arcuate
neurones to NPY. These neurones were determined to be GHRP-6-excited
neurones (see fig. 2.1.6 ). Each neurone was tested twice; the first time with
GHRP-6 (10~7M, 2-min bath application) and the second time withNPY (10 6M,
2-min bath application). In each case, the firing rate during the 10-min period
after NPY administration was significantly inhibited compared to the firing rate
during the 10-min period beforeNPY administration (t-test, p<0.001). Periods of
GHRP-6 and NPY treatments are indicatedwith bars.
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2.3.5.6 Effects of somatostatin on arcuate neurones
The responses to somatostatin were examined in recordings obtained from 22 arcuate neurones.
Each neurone was determined whether it responded to the somatostatin administration by
comparison between its mean firing rates in a control period (measured over 10 min
immediately before drug administration), and after exposure to somatostatin (measured from 2
to 12 min following the treatment). Initially, 10 arcuate neurones were tested with somatostatin
at 10" M for 2 min. Four of these neurones were significantly inhibited, and 6 were non-
responsive. Representative recordings of arcuate neurones that were significantly inhibited by
somatostatin are shown in fig. 2.1.17 (A).The mean firing rate of these arcuate neurones was
reduced by 0.39 spikes/s (19 %; from 1.86 ± 0.87 to 1.46 ± 0.72 spikes/s) (fig. 2.1.17 B).
Ten arcuate neurones were tested with somatostatin at the higher concentration of 10"7 M,
again for 2 min. Of these 10 neurones, 3 were inhibited, 1 was stimulated, and 6 were non-
responsive. The average firing rate of inhibited neurones was a 17.50 % decrease (data not
shown).
In addition, two arcuate neurones were tested with identical somatostatin administration, but
under low calcium condition. Both of them were inhibited. At the peak of inhibition, the mean
firing rate was decreased by 45.7 %. Thus, overall, 9 arcuate neurones (41 %) were shown to
be significantly inhibited by somatostatin at concentration of 10"7 M or less.
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B
"33 Somatostatin (108 M)
Fig. 2.1.17. Electrophysiological responses of arcuate neurones to
somatostatin. (A) Rate-meter record showing inhibitory effect of
-8
somatostatin. The arcuate neurone was tested with somatostatin at 10 M
for 2-min bath application. (B) Mean response of arcuate neurones that
were inhibited by somatostatin. Neurones were determined to be
inhibited according to their responses the same way as for NPY responses
[see fig. 2.1.16 (A)]. Their normalised mean firing rates rate were averaged
minute-by-minute (n=4 per each point).
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2.3.5.7 Responses of arcuate neurones to the absence of glucose
Responses of arcuate neurones to the absence of glucose were tested in extracellular
recordings. At the start, firing activity of twenty arcuate neurones was recorded with perfusion
of normal medium. Then, perfusion was switched from normal medium to glucose-free
medium either for 4 min (10 neurones) or 5 min (10 neurones). After that, perfusion was
switched back to normal medium.
Changes in firing rate from the period of 5 min immediately before glucose-free medium
perfusion to the period of 5 min (3 to 8 min) after the start of glucose-free medium perfusion,
were analysed. The minute-by-minute firing rates in these two periods were compared
statistically.
No significant difference between perfusion of glucose-free medium for 4 or 5 min was made.
Only 3 out of 20 neurones were significantly inhibited by more than 0.5 spikes/s (t-test,
p<0.02, data not shown). None of them was significantly excited by more than 0.5 spikes/s.
Overall, no significant change in mean firing rate of arcuate neurones was obtained after
perfusion of glucose-free medium (mean change of - 0.07 + 0.08 spikes/s, n = 20).
2.3.6 Electrophysiological studies of ventromedial hypothalamic neurones
2.3.6.1 Basal activity and activity patterns in the ventromedial hypothalamic
nucleus
Stable extracellular recordings were made from 90 spontaneously active neurones in the
ventromedial hypothalamic nucleus of the trimmed rat hypothalamic slice preparation. Each
neurone was recorded from a different slice, and was tested with application of secretagogues
alone or in combination with other drugs.
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Like arcuate neurones, all recorded hypothalamic neurones were spontaneously active, and
discharged with no conspicuous pattern - in particular no neurone fired phasically, and no
neurone fired very regularly. The mean of variation coefficients was 106 % which confirms
their highly irregular firing pattern. The mean spontaneous firing rate of these ventromedial
hypothalamic neurones was 0.90 ± 0.06 spikes/s (mean ± SEM; range 0.11 to 3.33 spikes/s).
The discharge patterns of these neurones were also studied by analysing the distributions of
interspike intervals in the same way as for arcuate neurones.
Most of the neurones analysed (90 %) had a clearly defined modal interspike interval. The
average modal interspike interval in the control period was 0.43 ± 0.05 s, and only 13.70 % of
them showed a modal interspike interval of less than 100 ms. Of the remainder, 86 % of these
neurones showed a more dispersed interspike interval histogram with a predominant interspike
interval greater than 100 ms. Firing pattern with bi-modal interspike intervals were also found
in 10 % of them. The differences ofmean firing rates and interspike intervals of neurones that
responded and did not respond to GHRP-6 were analysed, and are described in section 2.3.1.2.
2.3.6.2 Responses of ventromedial hypothalamic neurones following
administration of GHRP-6
Forty-seven ventromedial hypothalamic neurones were tested for their responses to GHRP-6.
Each neurone was determined whether it responded to the GHRP-6 administration by
comparison between its mean firing rates in a control period (measured over 10 min before the
administration), and after exposure to GHRP-6 (measured from 5 to 15 min after
administration). The minute-by-minute firing rates in these two periods were compared
statistically. Two initial representative recordings of ventromedial hypothalamic neurones that
were stimulated by two different concentrations ofGHRP-6 are shown in fig. 2.2.1 (A and B).
Figure A shows a recording of a neurone, stimulated by GHRP-6 (10"6 M) for 2 min, that
markedly increased its firing rate from 0.99 to 2.61 spikes/s, more than a 2-fold increase.
Figure B shows a different neurone stimulated by a lower concentration (10~7 M) of GHRP-6
for 2 min, again showing an increase in firing rate from 0.88 to 1.79 spikes/s, approximately a
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2-fold increase. After these pilot experiments involving tests of GHRP-6 at different
concentrations, the concentration of 10"7 M for 2 min was selected to be the condition of the
rest of the study.
The effects of GHRP-6 were examined on 47 neurones. To analyse the responses, and to
classify neurones as excited, inhibited, or non-responsive, the firing activity over a 10-min
control period were compared with the firing activity in the period 5-15 min after drug
application, for all cells, as previously described in the studies of arcuate neurones. Figure
2.2.2 shows the mean change in firing rate of each neurone tested, plotted in order of
magnitude. The population of ventromedial hypothalamic neurones was divided into three
groups according to their responses to GHRP-6. Two of the tested neurones (4.26 %) were
significantly inhibited by GHRP-6 (P < 0.02). Ten neurones (21.28 %) did not show any
significant change following administration of GHRP-6 (P= 0.05). Thirty-five neurones (75
%) showed a significant increase in firing rate following GHRP-6 (P< 0.02). The mean firing
rate of this group increased by 0.86 spike/s (113 %, from 0.76 ± 0.07 to 1.63 ± 0.16 spikes/s).
The basal firing patterns of these three classified groups of the ventromedial hypothalamic
neurones were then compared. The modal interspike interval of the discharge was taken as the
peak in interspike interval histogram of the 10-min period of recording before administration of
GHRP-6. The modal interspike intervals of neurones from these 3 groups were then plotted
against mean interspike interval (fig. 2.2.3). The excited neurones had mean firing rates which
were evenly scattered, mostly between 0 and 1.5 spikes/s with a mean ± SEM of 0.75 ± 0.07
spikes/s. Most of the excited neurones (32 of a total 35, 91 %) had uni-modal interspike
interval distributions with an average mode of 0.35 ± 0.04 s, whereas the rest 3 of excited
neurones had bi-modal interspike interval distributions. Non-responsive neurones had a mean
firing rate of 0.86 ± 0.16 spikes/s and an average modal interspike interval (averaged from 9 of
a total 10 neurones with uni-modal interspike interval) of 0.29 ± 0.07 s. The two inhibited
neurones had mean firing rates of 0.66 and 1.06 spikes/s, with modal interspike intervals of
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Fig. 2.2.1. Extracellular recordings of the firing rate of ventromedial hypothalamic
neurones following perfusion of the hypothalamic slices with GHRP-6. (A) A neurone
was stimulated with 10~6M for 2 min. (B) Another neurone was stimulated with the same
secretagogue at lower concentration (10" M) for 2min. The firing ratewas divided into 10-
s intervals and is expressed as spikes/s. In each case, the firing rate during the 10-min
period taken 5 to 15 min following GHRP-6 administration (averaged for 60x10-s
intervals) was significantly different from the firing rate of control period taken 10 min













































Fig. 2.2.2. (A) Ranking of changes in firing rate of 47 ventromedial hypothalamic
neurones followingGHRP-6 treatment. Mean firing rate ofeach individual neurone
during the 10-min period after GHRP-6 application (10"7M, 2-min) was normalised by
subtracting the mean firing rate of the control period (10-min period before the
application). Neurones were divided into 3 groups according to their responses.
Changes in firing rate after GHRP-6 treatment were statistically significant in the
inhibited and excited groups (t-test, p< 0.02), but not in the non-responsive groups.
Each bar represents the change in firing rate (± SEM) of one individual neurone
following GHRP-6 administration. Some non-responsive and excited neurones were
also testedwithNPY (10~6M) in the same recording. Responses toNPY were analysed
the same way as for GHRP-6 responses (c.f. Fig.). (B) Mean response of the excited
group following GHRP-6 treatment. Normalised mean firing rates of the excited
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Fig. 2.2.3. Relationship between mean and modal interspike interval of
basal firing activity of ventromedial hypothalamic neurones treated
with GHRP-6. Neurones were divided into 3 groups according to their
responses to GHRP-6 (lCf7M, 2-min bath application). For each cell, mean
andmodal interspike intervals were analysed from its control period (10min
before the treatment).
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In summary, excited and inhibited ventromedial hypothalamic neurones were had similar mean
firing rates. However, 14 of 15 neurones that showed a modal interspike interval of 0.4 s or
higher, were excited by GHRP-6. This might indicate that neurones with a high modal
interspike interval are likely to exhibit an excitatory response to the GHRP-6.
In addition, the analysis also showed no clear difference between the firing patterns of excited
and non-responsive neurones in term of regularity. The excited groups had a non-significantly
lower variation coefficient than that of non-responsive group (t-test, p = 0.05). The variation
coefficients of the excited and non-responsive groups were 99 ± 4 % and 118 ± 16 %
respectively.
The mean firing rates of excited neurones were plotted (fig. 2.2.2). The increase began as soon
as the peptide reached the brain slice, and during the period of drug washout, the response
increased progressively and peaked in approximately 10 min. At the peak, the mean firing rate
was approximately 1 spikes/s higher than the initial control level. The response remained
relatively stable above control levels for about 60 min after the administration.
The effects of GHRP-6 on the discharge patterns of ventromedial hypothalamic neurones were
analysed. The average variation coefficient decreased from a control level of 99 ± 4 % to 91 ±
6 % following administration of GHRP-6 (7.50 % decrease). Of 35 neurones excited by
GHRP-6, 22 neurones (63 %) showed a decrease in variation coefficient, which means they
increased regularity of their firing pattern following the administration of GHRP-6. The
remaining 13 excited neurones (37 %) showed an increase in variation coefficient. Figures
2.2.4 and 2.2.5 show recordings of two representative ventromedial hypothalamic neurones
with increased and decreased regularities respectively by GHRP-6). However, the overall
decrease in variation coefficient of these GHRP-6-stimulated group was not statistically
significant (t-test, P = 0.05). This indicates that the regularity of firing pattern of the
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Fig. 2.2.4. Effects of GHRP-6 on regularity of discharge pattern of a
representative ventromedial hypothalamic neurone. Upper panel illustrates the
ISI histogram compiled before (left) and after (right) bath application (2 min) of
GHRP-6 (107 M). The decrease in variation coefficient reflects an increase in
regularity of its discharge pattern after GHRP-6 treatment. Lower panel illustrates
the effects of GHRP-6 on firing rate of this neurone. Two bars indicate the periods of
control and GHRP-6 treatment ISI histograms.
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Control
variation coefficient = 126.72 %
GHRP-6
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Fig. 2.2.5. Effects of GHRP-6 on regularity of discharge pattern of a
representative ventromedial hypothalamic neurone. Upper panel illustrates the
ISI histogram compiled before (left) and after (right) bath application (2 min) of
GHRP-6 (107 M). The increase in variation coefficient reflects a decrease in
regularity of its discharge pattern after GHRP-6 treatment. Lower panel illustrates
the effects of the GHRP-6 on firing rate of this neurone. Two bars indicate the
periods ofcontrol and GHRP-6 treatment ISI histograms.
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2.3.6.3 Desensitisation to the effect of GHRP-6
Two ventromedial hypothalamic neurones that were stimulated by GHRP-6 were tested with a
second challenge of the peptide. The first exposure caused rapid activation during the washout
period (fig. 2.2.6). The increases in firing rate reached peaks and brief plateau periods, and
gradually declined to control levels. After a washout period of longer than 100 rnin with no
GHRP-6 in the perfusate, the neurones were challenged with a second exposure identical to the
first exposure. The second exposure also increased firing rate, but with a noticeable
attenuation. The mean increase in firing rate following the second exposure to GHRP-6 was
only 79 % of that of the first exposure.
2.3.6.4 Effects of NPY on GHRP-6-stimulated ventromedial hypothalamic
neurones
Thirty-nine ventromedial hypothalamic neurones were tested for their responses to NPY at 10"6
M for 2 min. Of the 39 neurones, 25 were neurones excited in response to GHRP-6. The
response of each neurone to NPY was determined by comparison between its mean firing rate
in a control period (measured over 10 min before drug administration), and after exposure to
NPY (measured from 2 to 12 min after treatment).
Figure 2.1.7 A shows the mean change in firing rate of each neurone tested, plotted in order of
magnitude. The population was divided into 3 groups. Twenty-five neurones (64 %) showed
significant inhibitory effects ofNPY, whereas 3 neurones (8 %) showed significant excitatory
effects of NPY. The remaining eleven neurones tested did not show any significant change in
firing rate (t-test, P< 0.05). Recordings of three representative GHRP-6-excited neurones that
were inhibited by NPY are shown in fig. 2.2.8, The inhibitory effects ranged from about 10 %
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Fig. 2.2.6. Rate-meter records showing reduction of firing rate of
ventromedial hypothalamic neurones in response to second challenge of
GHRP-6. Each neurones were treated twice with GHRP-6 (10~7 M) with at least




Fig. 2.2.7. (A) Ranking of changes in firing rate of39 ventromedial hypothalamic
neurones following NPY treatment. Mean firing rate of each individual neurone
during the 10-min period after theNPY application (10~6M, 2 min) was normalised by
subtracting the mean firing rate of control period (10-min period before NPY
application). Neurones were divided into 3 groups according to their responses.
Changes in firing rate (± SEM spikes/s) after NPY treatment were statistically
significant in the inhibited and excited groups (t-test, p< 0.03), but not in the non-
responsive group. Each bar represents the change in firing rate of one individual
neurone following NPY administration. (B) Mean response of the inhibited group
following NPY treatment. Normalised mean firing rates of inhibited neurones were



























Fig. 2.2.8. Electrophysiological responses of GHRP-6-excited ventromedial
hypothalamic neurones to NPY. These neurones were determined to be
GHRP-6-excited neurones [see fig. 2.2.2 (A)]. Each neurone was tested twice;
the first time with GHRP-6 (10~7M, 2-minbath application) and the second time
withNPY (10"6M, 2-min bath application). In each case, the firing rate during the
10-min period afterNPY application was significantly inhibited compared to the
firing rate during the 10-min period before NPY application (t-test, p<0.001).
Periods ofGHRP-6 andNPY applications are indicated with bars.
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The mean firing rates of inhibited neurones were plotted (fig. 2.2.7 B). The decrease was
maximal approximately 5 min after NPY administration. The mean firing rate of inhibited
neurones reduced by 0.63 spikes/s (49 %, from 1.29 ± 0.13 to 0.66 ± 0.11 spikes/s).
Twenty-five neurones that were excited by GHRP-6were also tested with NPY. Seventeen of
these (68 %) were inhibited, 1 was excited, and 7 were non-responsive to NPY. Thus the
majority of ventromedial hypothalamic neurones that were excited by GHRP-6 were inhibited
by NPY.
2.3.6.5 Effects of a NPY Y1 receptor antagonist on GHRP-6- and NPY-
responsive ventromedial hypothalamic neurones
Responses ofNPY Y1 receptor antagonist, L-753044-001J003, were examined in recordings of
six ventromedial hypothalamic neurones that responded to both administrations of GHRP-6
and NPY. After each neurone was stimulated and inhibited by GHRP-6 (10~7 M) and NPY
(10~6 M) respectively, they were therefore treated with the antagonist for 5 min. Then the
identical concentration and period of NPY was applied at 3 min after the pre-treatment of the
antagonist started. In one cell, pre-treatment with the antagonist at 10"8 M did not block the
inhibition by NPY (data not shown). A second ventromedial hypothalamic neurone was pre-
treated with two concentrations of the antagonist (l(f6 and 10"7 M). The higher concentration
was found to effectively block the inhibitory effect of NPY, whereas the lower concentration
did not (fig. 2.2.9). Thus, the antagonist concentration at 10"6 was selected for pre-treatment of
two different ventromedial hypothalamic neurones. In one of these cells, the NPY Y1
antagonist completely blocked the NPY inhibitory effects, whereas in the other cell there was
no clear effect.
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Fig. 2.2.9. Effects of NPY Y1 receptor antagonist (L-753044-001J003) on
inhibitory effect of NPY on ventromedial hypothalamic neurone. The neurone
was responsive to GHRP-6 (107M) and NPY (10~6M), and thereafter pretreated with
two concentrations of the antagonist (106 M and 10~7 M) for 5 minutes. After the
pretreatment, mixture of NPY and the antagonist at either 10"6 M and 10"7 M were
followed for two minutes. Periods ofpeptides and antagonist treatments are indicated
with bars.
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2.3.6.6 Effects of somatostatin on ventromedial hypothalamic neurones
The responses to somatostatin were examined in recordings from 15 ventromedial
hypothalamic neurones. The response of each neurone to somatostatin was determined by
comparison between its mean firing rates in a control period (measured over 10 min before the
administration), and after exposure to somatostatin (measured from 2 to 12 min following the
treatment).
Nine ventromedial hypothalamic neurones were tested with somatostatin at 10~7 M for 2 min.
Two neurones were inhibited, another 2 were stimulated, and 5 were non-responsive. The
inhibitory effects of somatostatin were seen in reducing the mean firing rate of neurones from
0.72 to 0.56 spikes/s (21 % decrease).
Six other ventromedial hypothalamic neurones were tested with somatostatin at a higher
concentration (lft6 M) for 2 min. Four of them were significantly inhibited and 2 were non-
responsive. Recordings of representative neurones inhibited by somatostatin are shown in fig.
2.2.10 A. The mean firing rate of the four inhibited ventromedial hypothalamic neurones was
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Fig. 2.2.10. (A) Electrophysiological response of a ventromedial hypothalamic
neurone to somatostatin. A representative neurone was inhibited by bath
application ofsomatostatin (10~6M, 2min). The firing rate during the 10-min period
following somatostatin administration was significantly different from the firing
rate before administration (t-test, p<0.01).The period of somatostatin treatment is
indicated with the bar. (B) Mean response of inhibited neurones following
somatostatin treatment. Normalised mean firing rates of inhibited neurones were
averagedminute-by-minute (n=4 per each point).
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2.3.6.7 Responses of ventromedial hypothalamic neurones to changes of
glucose concentration
Responses to glucose concentration changes were examined in recordings obtained from 43
ventromedial hypothalamic neurones. Neurones were first detected by their spontaneous
activity at 10 mM glucose in the medium. In the pilot experiment, fifteen of these neurones
were tested with transformation of glucose concentration from 10 to 20 or 10 to 0 mM. After
the transition from 10 to 20 mM, of 15 neurones, 1 was inhibited and 3 were excited. Whereas,
after the transition from 10 to 0 mM, of 13 neurones, 3 were inhibited and 1 was excited.
However, according to previous study, most neurones throughout the brain become silent at 0
mM glucose (Silver and Erecinska, 1994), so testing with glucose-free medium from the
beginning of experiments was impracticable. In addition, examine with too low concentration
below the physiological range might lead to neuronal activation by mechanisms that perhaps
function to protect the brain during hypoglycemia, rather than through physiological
glucoceptive mechanisms (Silver and Erecinska, 1994).
A subpopulation of neurones in the ventromedial hypothalamus became silent when the
extracellular glucose concentration was decreased from 10 mM to 5 mM and become active
again after raising the glucose concentration to 20 mM (Yang et al., 1999).
In some recordings, transition from 10 to 5 mM glucose was applied before the transition from
5 to 0 mM to avoid sudden extreme change. Changes in firing rate following transitions from
10 to 5, and 5 to 20 or 5 to 0 mM were analysed. Each neurone was determined whether it
responded to the transition by comparison between its mean firing rates in a control period
(measured over 5 min before the transition), and after transition (measured from 3 to 7 min
following the transition). The minute-by-minute firing rates in these two periods were
compared statistically using t-test.
A variety of responses of ventromedial hypothalamic neurones were seen. However, there was
no typical pattern of response to interpret following the transition from 5 to 20 and from 5 to 0
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mM. The most consistency was found in responses of neurones in the transition from 10 to 5
mM glucose.
In 20 neurones tested for transition from 10 to 5 mM glucose, 7 neurones (35 %) were
significantly inhibited, 1 (5 %) was excited, and 12 (60 %) were non-responsive (P< 0.03).
Two representative ventromedial hypothalamic neurones that were responsive by the
transitions are shown in fig. 2.2.11 (A and B). Figure A shows a neurone that was inhibited,
whereas fig. B shows a different neurone excited by the transition from 10 to 5 mM glucose.
The firing rates of inhibited neurones were averaged and plotted (fig. 2.2.12). The mean firing
rate of inhibited neurones decreased by 0.27 spikes/s (28.4 ± 4.3 % inhibition, from 1.19 ± 0.37
to 0.92 ± 0.36 spikes/s).
Some neurones responded to transition from 5 to 20 mM glucose with a rapid burst of activity,
followed by a return to normal activity. This kind of brief, transient responses, when firing rate
was analysed, did not show any significant change in firing rate by the method chosen for
analysis, and so these cells are included in the non-responsive group. However, it should be
























Fig. 2.2.11. Rate-meter records showing the effects of changes in glucose
concentration on ventromedial hypothalamic neurones. Superfusate glucose
concentration was switched from normal concentration of 10 to 5 and 20mM while
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Fig. 2.2.12. Mean inhibitory response (± SEM) ofventromedial hypothalmic
neurones to transition of superfusate glucose concentration from 10 to 5
mM.. Normalised mean firing rates ofinhibited neurones were averaged minute-
by-minute (n= 8 per each point). Periods oftreatment are indicatedwith bars.
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2.4 Discussion
This study reveals that arcuate neurones in vitro display spontaneous firing characteristics very
similar to those described in vivo. In particular, the low spontaneous firing rate of
approximately 1 spike/s is very similar to discharge rates of arcuate neurones in vivo in
anaesthetised rats (Dickson et al., 1995b).
The effects of both the prototype secretagogue GHRP-6, and the non-peptide agonist L-
144,446 on the electrical activity of hypothalamic neurones were compared in this study. At a
concentration of 10"8 M, L-144,446 produced a similar level of increase in firing rate to GHRP-
6 at a ten-fold higher concentration of 10"7 M. Their patterns of activation were found to be
very similar in terms of latency and duration.
Both GHRP-6 and L-144,446 had very prolonged effects, maintaining excited firing rates
above baseline levels for over an hour after washout. This slow onset and prolonged duration
of response is very similar to the responses seen in anaesthetised rats following systemic
administration of GHRP-6 (Dickson et al., 1995b). In particular, it is noticeable that both
secretagogues stimulated arcuate neurones with the same latency period both in brain slice and
in rat brain. Thus it appears that the latency and time course of the responses to secretagogue
observed in vivo do not merely reflect the time course of penetration of these compounds into
the brain, and the time course of their subsequent degradation or inactivation. Rather it would
appear that in vivo, there is no observed delay in neuronal responsiveness beyond that seen in
vitro following direct application. Moreover, the long duration of response does not require the
continued presence of the secretagogue.
GHS-R is expressed in ventromedial hypothalamic neurones, and its expression is sensitive to
GH (Bennett et al., 1997). GHS-R was found to be localised in GHRH-expressing
ventromedial hypothalamic neurones (Tannenbaum et al., 1998a). However, it has not been
consistently demonstrated that Fos expression is induced by GHS in the ventromedial
hypothalamus in vivo. Nevertheless, in the present experiments, effects of NPY were seen in
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greater number of ventromedial hypothalamic neurones than arcuate neurones. So far, both
receptors for NPY and GHS were localised on ventromedial hypothalamic neurones but co-
localisation of them has not been established. As most GHRP-6-excited neurones in the
ventromedial hypothalamus were also inhibited by NPY, neurones in this nucleus seem likely
to contain receptors for both peptides.
Lack of clear evidence of Fos expression induced by GHS in the ventromedial hypothalamus
led to doubt as to whether the GHS receptors on neurones in this area are functionally coupled
to electrical activity. In this study, the activation of electrical activity of ventromedial
hypothalamic neurones by GHRP-6 provided clear evidence that these receptors are functional,
and they seem likely to be coupled in a similar way to those in the arcuate nucleus. Thus, it is
still unclear why Fos expression is not induced following GHS administration in vivo. One
possibility is that some effects of GHS in vivo lead indirectly to inhibition of ventromedial
hypothalamic neurones. In particular, it seems possible that systemic administration of GHRP-
6 stimulates NPY-containing arcuate neurones that project their fibres to inhibit NPY-receptor-
containing ventromedial hypothalamic neurones.
Sixty-eight percent of GHRP-6-excited ventromedial hypothalamic neurones, compared to 40
% of GHRP-6-excited arcuate neurones, were significantly inhibited by NPY. Clearly the
responsiveness of neurones to NPY does not alone determine how they will respond when
NPY neurones in the same or other brain regions are activated. The key questions are, to which
neurones do the NPY neurones that are activated by GH secretogogues project? and which
factors are co-expressed by these neurones?. Although some NPY neurones in the arcuate
nucleus project to the paraventricular nucleus, few of these express Fos after GHS
administration (Dickson and Luckman, 1997). Most of the GHS-responsive neurones in the
arcuate nucleus are neurosecretory in that they project to the median eminence (Dickson et al.,
1996), but these neurones may have other projections. Certainly there is a high density of NPY
fibres in the ventromedial hypothalamic nucleus.
NPY neurones in the arcuate nucleus co-express many different factors, most conspicuously
AGRP, which like NPY stimulates feeding and hence is presumed to have similar cellular
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actions, and GABA, with potent inhibitory actions likely to supplement the inhibitory effects of
NPY described here. Thus it is possible that systemic administration of GHRP-6 stimulates
NPY-containing arcuate neurones that project to and inhibit NPY-receptor-containing
ventromedial hypothalamic neurones.
Since inhibitory effects of somatostatin were also detected in ventromedial hypothalamic
neurones in vitro, it is also possible that activation of somatostatin neurones by GHS may
counteract the excitatory effects of GHS in the ventromedial hypothalamus in vivo. In the
arcuate nucleus, Fos expression induced by GHRP-6 can be attenuated by exogenous
administration of somatostatin (Dickson et al., 1997). In the mouse, though not in the rat,
systemic injection of GHS induces Fos expression in the periventricular nucleus, probably in
the neurosecretory somatostatin neurones. Periventricular somatostatin neurones express
receptors for growth hormone, and their activation by GHS appears to be secondary to
induction of growth hormone release by GHS. Exogenous growth hormone attenuates GHS-
induced Fos expression in the arcuate nucleus in mice, and this effect is absent in transgenic
mice that lack somatostatin SSTR2 receptors, hence it seems likely that following GHS
activation of GHRH neurones, growth hormone is released and in feeds back upon
periventricular somatostatin neurones that in turn inhibit GHRH neurones (Zheng et al). In rats
treated chronically with i.c.v. GHRP-6 there is a sustained upregulation of somatostatin mRNA
expression in the periventricular nucleus, consistent with activation of somatostatin release in
the rat following GHS treatment (Bailey et al., 1999a).
Whether periventricular somatostatin neurones regulate ventromedial hypothalamic neurones is
not known however. There are also somatostatin cells in the arcuate nucleus, and this
population projects centrally rather than to the median eminence (Baker and Herkenham,
1995). However, these neurones do not express c-fos mRNA in response to systemic GHS
(Dickson and Luckman, 1997), and somatostatin mRNA expression in the arcuate nucleus,
unlike that in the periventricular nucleus, is unchanged following chronic i.c.v. infusion of
GHS (Bailey et al., 1999a).
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Most arcuate neurones that express Fos protein following GHRP-6 injection are likely to be
neurosecretory neurones (Dickson et al., 1996). According to the effects of L-144,446 on
arcuate neurones which showed similar characteristics to those that responded to GHRP-6, L-
144,446 was also assumed to have effect on neurosecretory neurones as well. Two arcuate
neurones that were activated by L-144,446 showed a clear bi-modal interspike interval pattern
with the short modal interspike interval of 0.02 s for both neurones and long interval of 0.34
and 0.5 s respectively. These two neurones had similar firing patterns to that of arcuate
neurones that was antidromically-identified as projecting to the ipsilateral paraventricular
nucleus (Honda et al., 1999). This study also demonstrated that 20 % of arcuate neurones that
were retrogradely-labelled from the paraventricular nucleus were Fos-positive following
GHRP-6 injection. It shows the consistency of findings of characteristics of firing pattern of
arcuate neurones.
Almost half of the arcuate neurones tested were inhibited by NPY. In addition, NPY Y1 or Y2
receptors were found to be localised in the arcuate nucleus (Cheng et al., 1998). Dual
chromogenic and autoradiographic in situ hybridisation showed co-expression of GHS-R-
mRNA with other peptides, including GHRH and NPY mRNA (Willesen et al., 1999). GHS-R
mRNA was found to be expressed in 94 % of neurones expressing NPY, whereas only 20-25 %
of GHRH mRNA-expressing neurones contained GHS-R mRNA. Thus most GHS-R
expressing neurones might have other functions rather than the control of GH secretion. In
particular, GHS-R expressing arcuate neurones that also contain NPY may play an important
role in regulating food intake. It was demonstrated that secretagogue-induced food intake was
blocked by NPY Y1 receptor antagonist (Lawrence et al., 2002), suggesting that the orexigenic
effects of GHS may be mediated via NPY neurones in the arcuate nucleus.
The ventromedial hypothalamus is known to be sensitive to glucose (Yang et al., 1999), and
responses of ventromedial hypothalamic neurones to glucose were also demonstrated in this in
vitro study. Altogether, effects of GHRP-6, NPY and glucose were clear in ventromedial
hypothalamic neurones. It was thought that neurones in this region responds to situation such
as negative energy balance that leads to production of NPY in the arcuate nucleus and finally
induces food intake in animal. However, lesions of the ventromedial hypothalamus of mice did
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The electrophysiological experiments described in Chapter 2 showed inhibitory effects ofNPY
on arcuate neurones and on ventromedial hypothalamic neurones. The co-localisation of GHS
receptor and NPY mRNA in the arcuate nucleus of the rats (Willesen et al., 1999) means that
arcuate neurones might be subject to inhibitory auto-regulation by NPY during exposure to GH
secretagogues, and that GH secretagogues may result in NPY release in other brain areas. Thus
although our in vitro study showed that the electrophysiological activity of ventromedial
hypothalamic neurones was significantly activated by GH secretagogues, in vivo this excitatory
action may be over-ridden by the inhibitory effects ofNPY released from arcuate neurones.
The effects ofNPY on these brain regions also reveal extensive actions of this orexigenic agent
that has been regularly found in previous behavioural studies (Tanaka et al., 1994). Significant
inhibitory effects of NPY on secretagogue-stimulated neurones in vitro suggests the presence
NPY receptors in these areas, and suggest that the effects of these two orexigenic agents, NPY
and GH secretagogues, converge on the same neurones at these sites. GH secretagogues are
thought to activate NPY neurones in the arcuate nucleus (Dickson and Luckman, 1997), but the
effects of these two orexigenic agents seem to oppose each other at the level of the single cell
in both the arcuate nucleus and the ventromedial hypothalamus.
To understand the physiological significance of these observations, it is important to go beyond
pharmacological classification of their effects and to look at the physiological role played by
the different pathways. Is it possible that, in vivo, GH secretagogues do not activate
ventromedial hypothalamic neurones because the direct action of secretagogues on
ventromedial hypothalamic cells is opposed by NPY released from arcuate neurones? Does
NPY released by arcuate neurones act in either the arcuate nucleus or in the ventromedial
hypothalamus? Further investigation of the effects of the secretagogue GHRP-6, NPY and
NPY Y1 receptor antagonist in vivo, using immunohistochemical techniques to map the
expression of Fos protein as an index of neuronal activation should provide clarification as to
how these brain areas respond to these compounds in vivo.
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3.1.1 The hypothalamus: a site of homeostatic regulation
The hypothalamus has been a major focus of studies directed at investigating the mechanisms
of control of energy balance in mammals. Many studies have confirmed that feeding regulation
is a major function of the hypothalamus. The arcuate nucleus, the ventromedial hypothalamus
and the lateral hypothalamus are all hypothalamic regions that exhibit a response to reduced
glucose concentration (Funahashi et al., 1999). Additionally, the detection of Fos-like
immunoreactivity in paraventricular and ventromedial hypothalamic nuclei of rats infused with
glucose (4 mg/kg/min) supports the presence of a subpopulation of glucose-responsive neurons
in these regions (Brogan et al., 2000). Double-immunostaining studies have revealed that the
arcuate nucleus and ventromedial hypothalamus contain leptin receptor-like immunoreactive
neurons that are innervated by orexin-like immunoreactive neurons (Funahashi et al., 2000).
Both leptin and orexin have been recently proposed to play major physiological roles in
feeding regulation; leptin inhibits feeding while orexin A and orexin B stimulate it..
Furthermore, several nuclei in the hypothalamus express a transcript of fibroblast growth
factor-5 (FGF-5), which is subjected to regulation by food deprivation (Li et al., 1999).
3.1.2 Brain regions involved in feeding behaviours
Many types of peptides regulate food intake. Among these, NPY is the most potent inducer of
food intake. It is primarily synthesised in neurones of the arcuate nucleus that project to the
paraventricular nucleus and dorsomedial nucleus of the hypothalamus (Dryden et al., 1996).
Significant differences between concentrations of NPY in hyperphagic obese and lean
normophagic Zucker rats are found in the arcuate nucleus, paraventricular nucleus and
suprachiasmatic nuclei, whereas peripheral NPY is not modified (Beck et al., 1990a). It might
be concluded that excessive food intake regulation is associated with central NPY-ergic
dysregulation. The paraventricular nucleus is hypothesised to be the primary site of NPY
action because the anticipated increase and decrease in NPY concentrations, in response to
food deprivation followed by ad libitum food intake, occurred only in this site (Kalra et al.,
1988). This idea was supported by radioimmunoassay studies of tissue NPY content, showing
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that, as well as in the arcuate nucleus, increases ofNPY content in the paraventricular nucleus,
ventromedial hypothalamus and dorsomedial hypothalamus in obese Zucker rats were also
observed (McKibbin et al., 1991). This evidence suggests that extensive interneural
communication is involved in the coordination of diverse feeding regulation.
It has been proposed that increased NPY activity in the arcuate nucleus might be a result of the
decreased circulating levels of insulin and glucose associated with a fast. Especially in the
ventromedial hypothalamus, some neurones were found to be sensitive to glucose
concentration changes (Yang et ah, 1999). However, lesion of the ventromedial hypothalamus
by gold thioglucose (GTG), which appears to act on glucose-responsive neurones, did not
prevent the increase of NPY mRNA expression by fasting in the arcuate nucleus (Bergen and
Mobbs, 1996). This suggests that GTG-sensitive ventromedial hypothalamic neurones play
little part in the fasting-induced induction of NPY mRNA expression. By contrast, disruption
of neural signaling in the ventromedial hypothalamus of rats by microinjection of the
neurotoxin, colchicine, results in rapid and transient hyperphagia and body weight gain and a
decrease in NPY content in the paraventricular nucleus (Kalra et ah, 1997).
NPY Y1 receptors appear to mediate at least some of the effects of NPY on feeding. The Y1
receptor antagonist 1229U91 suppressed feeding significantly in rats induced to be
hyperphagic by microinjection of colchicine in the ventromedial hypothalamus (Kalra et ah,
1997). 1229U91, when co-administered with NPY, inhibited NPY-induced food intake in rats
(Ishihara et ah, 1998). The non-peptide Y1 receptor antagonist BIBP3226 also significantly
reduced the intake of highly palatable diet and food intake stimulated by fasting (Kask et ah,
1998). In addition, J115814, a potent and selective Y1 antagonist (i.v.) significantly suppressed
feeding induced by NPY (i.c.v.) in satiated rats (Kanatani et ah, 2001). Similar findings have
also been observed in studies using G1264879A, a non-selective NPY-Y1 receptor antagonist
(Danielsa et ah, 2001). The role of Y1 receptors on feeding regulation was supported when
antisense oligonucleotides to NPY-Y1 receptor, but not antisense to NPY, delivered to the
ventromedial hypothalamus, suppressed feeding behaviour (Lopez-Valpuesta et ah, 1996).
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However, the Y1 receptor is not the only NPY receptor subtype that mediates effects of NPY
on food intake. The first Y5 receptor-selective analogue of NPY, which was developed and
found to have high affinity for the NPY Y5 receptor, also significantly stimulated feeding in
rats (Cabrele et al., 2000). Pharmacological analysis showed that rat and human Y5 receptors
have high affinity for the peptides that elicit feeding (Hu et al., 1996).
Zucker rats are a well-documented model of early-onset obesity, and have a hyperactive
hypothalamic NPY system. Binding assay of NPY to hypothalamic homogenates of obese rats
was reduced by 56 % compared with lean rats (McCarthy et al., 1991). This finding suggests
that NPY receptors undergo down-regulation in response to the increased hypothalamic NPY
activity. The Y5 receptor, a novel NPY receptor subtype, has been proposed to specifically
mediate hyperphagia (Gerald et al., 1996) was reported to be selectively down-regulated in
several hypothalamic brain regions especially in the arcuate nucleus of Zucker rats
(Widdowson, 1997). In addition, restriction to 60 % of normal daily food intake over 10 days,
or making obese by feeding male Wistar rats with high-calorie diet resulted in down and up-
regulation of NPY Y5 receptor respectively (Widdowson et al., 1997). This study also found
similar down and up-regulations of NPY Y2 receptors. The finding suggests that there is a
regional increase in NPY release during negative energy balance, and a reduced regional
release of NPY in positive energy balance. In studies using immunohistochemistry and in situ
hybridisation, the number of Y1 receptor immunoreactive neurones and Y1 receptor mRNA
level in the arcuate nucleus of rats decreased after food deprivation (Cheng et al., 1998). By
contrast, fasting did not significantly change Y2 receptor mRNA expression in this area. A
similar increase of Y1 receptor mRNA expression in the paraventricular and arcuate nuclei was
observed in response to supplementing the drinking water with 10 % glucose for 72 h
(Zammaretti et al., 2001). These results support the view that Y1 receptors in the arcuate




This study investigated the effects of NPY, Y1 receptor antagonist and the classical GH
secretagogue GHRP-6 on Fos expression the hypothalamus in vivo. From the
electrophysiological results, we predicted that NPY administration should block Fos activation
in the arcuate nucleus in response to GHRP-6, and also predict that Y1 antagonist should
potentiate Fos expression in response to GHRP-6 in both the arcuate nucleus and the




Adult male Sprague Dawley rats were maintained in a controlled environment with ad libitum
access to food and water (see Method 2.1.). On the day of experiments, rats were anaesthetised
with sodium pentobarbitone (sagatal, 0.5 ml/kg i.p.). This anaesthetic does not, by itself,
induce Fos expression in any hypothalamic nuclei of rats (Takayama et al., 1994). An
intracerebroventricular (i.e.v.) guide canula (23 gauge; Plastics One, USA) was positioned in
the right lateral ventricle (co-ordinates: 1.6 mm lateral, 0.6 mm posterior to bregma, 4.5 mm
below the surface of the skull). An intravenous (i.v.) canula was inserted into the right jugular
vein. After the end of surgery, rats were maintained under anaesthesia for at least 2 h before the
experiment.
3.3.2 Experimental Methodology
Rats were given an i.c.v. infusion of either vehicle (aCSF), NPY (4.68 nM in aCSF; Tocris,
UK) or Y1 receptor antagonist (30.7 nM in aCSF; Merck) at a flow rate of 1.27 pl/min for 45
min. Fifteen minutes after the start of the i.c.v. infusion, rats were given an i.v. injection of
either vehicle (0.2 ml sterile saline) or GHRP-6 (50 pg in 0.2 ml). Rats treated with aCSF
(i.c.v.) and sterile saline (i.v.) were used as control rats. Ninety minutes after the i.v. injection,
rats were deeply anaesthetised and perfused transcardially with chilled 0.1 M PB, followed by
chilled fixative solution (4% paraformaldehyde in 0.1 M PB). Brains were removed and
postfixed overnight in the same fixative solution at 4°C. They were then transferred to sucrose
solution (30% sucrose in 0.1 M PB) for cryoprotection until they sank. Brains were frozen on
dry ice and stored at -70°C until processed for immunohistochemical localisation of Fos
protein. For-positive control rats, they were injected (i.p.) with 4.0 ml/kg of hypertonic saline
solution (1.5 M NaCl)
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3.3.3 Immunohistochemistry for Fos protein
Coronal sections (40 jam) were cut through the hypothalamus using a microtome. This entire
process was performed in darkness in order to protect the fluorescent tracer from decay.
Sections were washed in 0.1 M PB pH (7.4) for 5 min at room temperature (RT). Endogenous
peroxidase was deactivated by incubation of the sections with methanol solution (20%
methanol, 0.2% TritonXlOO (TxlOO) and 1% hydrogen peroxidase (H2O2: in 0.1M phosphate
buffer) for 15 min at RT. Sections were then washed twice with 0.2 M PBT (0.2 M PB and
0.2% TxlOO) for 7.5 min each.
Before the Fos antibody incubation, sections were incubated with 1% normal sheep serum in
PBT for 1 h at RT to prevent non-specific binding. Then they were incubated in Ab-2 Fos
antibody (Rabbit polyclonal Ab-2 Fos, Oncogene Sciences; diluted 1:1000 in 1% normal sheep
serum, 0.2% TxlOO and 0.1 M PB) for 36 h approximately at 4°C. Sections were washed with
0.1 M PBT (0.1 M PB and 0.2% TxlOO) 6 times for 5 min each.
The antibody-antigen complex was localised with an incubation in secondary antibody
(Biotinylated anti-rabbit immunoglobulin, Vector; diluted 1:100 and normal goat serum,
Vector; diluted 3:100, in PBT) for 1 h at RT and followed by an incubation in Avidin DH
(Biotinylated horseradish peroxidase, Vector; diluted 1:50 in PBT) for 1 h at RT. After that,
sections were washed with PBT for (5x5 min each). Next, they were rinsed with 0.1 M
sodium acetate buffer (pH 6.0) for 5 min.
Immunolabelling was visualised by an incubation in chromagen solution [nickel ammonium
sulphate (0.25 mg/ml), diaminobenzidine (0.25 mg/ml), 4% glucose (w/v), 0.08% ammonium
chloride (w/v) and 0.003% glucose oxidase (w/v)] for 10 min approximately (see solution
preparation). Fos immunoreactive nuclei appeared as dark purple/black nuclei. The reaction
was terminated with 0.1 M sodium acetate buffer for 5 min. Sections were then washed with
H20 for 5 min and finally rinsed with 0.1 M PB for 5 min. Sections were mounted onto
gelatinised slides and air dried. They were dehydrated through a series of alcohols (50%, 70%,
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90%, 95%, 100%, 100%). They were finally submerged in xylene for 5 min and transferred
into another clean xylene for mounting (BDH).
3.3.4 Quantitative analysis
The slides were coded by covering identifying numbers with masking tape and assigned
random numbers before quantification to prevent bias. The sections were viewed under a light
microscope (xlO objective) and Fos positive nuclei were counted in the arcuate and
ventromedial hypothalamic nucleus on both the left and right sides. Data are expressed as mean
± SEM. T-test was used to compare the statistical differences between numbers of Fos positive
neurones of different groups.
3.4 Materials
Stock solution of phosphate buffer (1 M PB)
Phosphate buffer (1 M) contains 11.5 % w/v disodium hydrogen orthophaphate 2-hydrate
(Na2HP04.2H20, AnalaR; BDH) and 2.72 % w/v sodium dihydrogen orthophosphate 1-hydrate
(NaH2P04.H20, AnalaR; BDH). For a final volume of 1000 ml, these two chemicals were
added to 900 ml ddH20 and dissolved. The solution was adjusted to pH 7.4 with concentrated
hydrochloric acid or sodium hydroxide. Finally, the volume was made up to 1000 ml with
ddH20. This solution was later diluted to make up further diluted phosphate buffer solutions.
Heparinised phosphate buffer
Heparinised phosphate buffer was prepared by adding 129 mg heparin (Sigma H0777, 500,000
units) to 1000 ml of 0.1 M phosphate buffer.
4 % paraformaldehyde in 0.1 M phosphate buffer
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4 % paraformaldehyde solution contains 1.15 % w/v Na2HP04.2H20, 0.272 % w/v
NaH2P04.H20 and 4.0 % w/v paraformaldehyde (CH2; Sigma). These salts were prepared in
ddH20, and pH was adjusted to 7.3-7.4.
0.1M phosphate buffer + 0.2 % Triton X-100 (PBT)
Two ml of Triton X-100 is added to 1000 ml 0.1 M PB and thoroughly mixed on a stirrer.
1% normal sheep serum in 0.1 PBT
For 100 ml, 99 ml 0.1 M PBT was added with 1 ml normal sheep serum.
Hydrogen peroxide block in PB
Hydrogen peroxide solution was prepared in 0.1 M PB, containing 20 % methanol, 0.2 %
Triton X-100 and 1 % H2O2.
Primary antibody for Fos protein
Rabbit polyclonal anti Fos (Ab-2 Fos, Oncogene Sciences) was diluted 1: 1000 in buffer
containing 1 % normal sheep serum, 0.2 % Triton X-100 and 0.1 M PB.
Secondary antibody
Secondary antibody for was prepared by using Vector stain elite kit rabbit IgG (Vector labs PK
6101). Secondary antibody mixture contained 1 % v/v Biotinylated anti-rabbit
immunoglobulin, 3 % v/v normal goat serum and 0.1 M PBT.
Avidin-biotinylated horseradish peroxidase complex (ABC)
ABC solution was prepared by using ABC kit rabbit IgG's (Vector labs PK 6101). The
solution was made in PBT and contained 2 % v/v avidin DH, 2 % v/v biotinylated horseradish
peroxidase.
Solution for visualisation of the glucose oxidase-Nickel-DAB method.
Amounts of chemical for a total volume of 100 ml
50 ml of 0.2 M sodium acetate buffer
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2.5 g nickel ammonium sulphate (BDH 101674A)
0.4 g glucose (Sigma G7528)
0.08 g ammonium chloride (BDH A4514)
25 mg in 1 ml diaminobenzedine (DAB) is added to 49 ml dH20
0.003 g glucose oxidase type VII-s (Sigma G7016), kept at -20 °C
Method
A) Dissolve 2.5 g Nickel ammonium sulphate in 50 ml sodium acetate
B) Add the glucose (0.4 g) and ammonium chloride (0.08 g) to the nickel
Solution
C) Add the 50 ml DAB solution
D) Add the glucose oxidase immediately before use
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3.5 Results
3.5.1 Fos-like immunoreactivity in the arcuate nucleus induced by GHRP-6
Immunohistochemical visualisation of Fos-like immunoreactivity in rats given an i.v. injection
of GHRP-6 (50 pg), showed dense nuclear staining of selective cell nuclei in the arcuate
nucleus. Nuclear staining in the arcuate nucleus was similar to that observed in supraoptic
nucleus of brain slices of rats treated with i.p. injection of hypertonic saline (1.5 M NaCl, 4
ml/kg) (fig. 3.1A). Patterns of neuronal activation demonstrated by Fos expression in the
supraoptic nucleus after i.p. injection of hypertonic saline have been examined extensively in
previous studies (Giovannelli et al., 1992).
Intravenous injection in rats of 50 pg GHRP-6 caused a staining of selective cell nuclei in the
arcuate nucleus (fig. 3.1C). The treatment significantly increased Fos-like immunoreactivity in
the arcuate nucleus to 13.9 ± 2.8 positive neurones per arcuate nucleus section, compared to
2.5 ± 0.5 in saline-treated rats (fig. 3.1B) (mean ± SEM, /?<0.01, t-test). When expressed as
percentage increase, compared to basal level, GHRP-6 significantly increased Fos-like
immunoreactivity to 455 %.
3.5.2 Effects of NPY alone, and together with GHRP-6 on Fos-like
immunoreactivity in the arcuate nucleus
Intracerebroventricular injection of NPY (4.68 nM) alone in rats did not induce a significant
change in Fos-like immunoreactivity in the arcuate nucleus compared with aCSF infused rats
(fig. 3.ID). Approximately 2 Fos-like positive neurones per arcuate nucleus section were seen
after NPY injection, which was similar to the basal level of expression. In rats pre-treated with
aCSF, treatment with GHRP-6 caused, as shown previously (Dickson et al., 1996), an increase
in number of Fos-like immunoreactivity up to approximately 14 positive neurones per arcuate
nucleus section. By contrast, in rats pre-treated with NPY, i.v. injection of GHRP-6 induced
only about 6 Fos-like positive neurones per section in the arcuate nucleus (fig. 3.IE). Thus,
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NPY pre-treatment significantly attenuated GHRP-6-induced Fos-like immunoreactivity by
60.7 % of that of saline-pre-treated rats (p<0.01, t-test).
3.5.3 Effects of NPY Y1 receptor antagonist, L-753044-001J003, on Fos-like
immunoreactivity in the arcuate nucleus
Intracerebroventricular injection of the NPY Y1 receptor antagonist (30.7 nM) in rats, by
itself, did not significantly enhance Fos-like immunoreactivity in the arcuate nucleus as
compared with saline-treated rats (data not shown). The average number of Fos-like positive
neurones seen in the arcuate nucleus after the Y1 receptor i.c.v. injection and followed by i.v.
injection of saline was 3.4 ± 0.32 (36.7 % over basal level). When given for pre-treatment
before GHRP-6 treatment, the Y1 antagonist, produced a small, non-significant attenuation of
the GHRP-6 induction of Fos-like immunoreactivity in the arcuate nucleus (by 25.1 %; data
not shown).
In chapter 2, the distribution of secretagogue-responsive neurones throughout the arcuate
nucleus was found to be uneven, when assessed electrophysiologically. Additionally, the
density of spontaneously active neurones throughout the length of the arcuate nucleus detected
extracellularly was also non-uniform. In this study, the effects of GHRP-6, NPY and Y1
receptor antagonist on Fos-like immunoreactivity in the arcuate nucleus were also analysed by
focusing on specific parts of the arcuate nucleus. Levels of Fos-like immunoreactivity in the
arcuate nucleus were analysed in 4 regions: from A to D (A: 1.8 - 2.3 mm, B: 2.3 - 2.8 mm, C:
2.8 - 3.3 mm, D: 3.3 - 4.16 mm posterior to bregma).
Figure 3.2A shows levels of Fos-like immunoreactivity induced by various treatments in areas
A, B, C and D of the arcuate nucleus. The number of Fos-like immunoreactive neurones
induced by GHRP-6 was greater in area B than in area A, and higher still in area C. Area D
showed slightly fewer Fos-like immunoreactive neurones than area C. Similar patterns of
variation in the density of Fos-like immunoreactive neurones were also observed in brain slices
of rats pre-treated with either NPY or Y1 receptor antagonist and followed by treatment with
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GHRP-6. The total average number of Fos-like immunoreactive neurones in the arcuate










A Hypertonic saline (i.p.) .
Fig. 3.1. Representative Photomicrographs showing Fos immunoreactivity observed
in the arcuate nucleus of rats. Dense nuclear staining are seen in the supra optice nucleus
of rat induced by hypertonic saline injection (1.5 M NaCl, 4 ml/kg, i.p.). Rats were pre-
treated (i.c.v.) and injected (i.v.) as indicated. 3V: third ventricle, ME: median eminence.















































































Fig. 3.2. Effects of GHRP-6 and NPY on the number of Fos positive neurones in the
arcuate nucleus. (A) The total number ofFos positive nuclei per arcuate nucleus section is
shown in 4 parts ofthe arcuate nucleus; A, B, C, and D (from the anterior to posterior). A: 1.8
- 2.3 mm, B: 2.3 - 2.8 mm, C: 2.8 - 3.3 mm, D: 3.3 - 4.16 mm posterior to bregma. (B) Bar
graph shows the total number of Fos-positive nuclei per arcuate nucleus. Rats were pre-
treatedwith i.c.v. injection ofeither aCSF orNPY (4.68 nM) and followedwith i.v. injection
(2 ml) of either vehicle (saline) or GHRP-6 (50 pg). All data are the mean ± SEM (n = 6 in
each group). Statistical significance of differences compared with aCSF/Veh group: *=
p<0.05 (Post-hoc t-test)
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3.5.4 Induction of Fos-like immunoreactivity in the ventromedial hypothalamic
nucleus following i.c.v. injection of NPY Y1 receptor antagonist, L-753044-
001J003
The ventromedial hypothalamic nucleus showed a basal level of Fos-like immunoreactivity of
3.99 ± 1.0 positive neurones/section (fig. 3.IB). Unlike in the arcuate nucleus, neither pre-
treatment of NPY nor treatment with GHRP-6 (fig. 3.3A1), had any significant effect on Fos-
like immunoreactivity in the ventromedial hypothalamic nucleus.
In rats pre-treated with the Y1 receptor antagonist and followed by saline, Fos-like
immunoreactivity in the ventromedial hypothalamic nucleus was markedly increased (fig.
3.3A2). The average number of Fos-like immunoreactive neurones of this group was 16.7 ± 4.1
nuclei/nucleus section which was 318 % higher than that of rats pre-treated with aCSF and
followed with saline treatment. However, when followed with injection of GHRP-6, the Y1
receptor antagonist did not sustain high level of Fos-like immunoreactivity (fig. 3.3A3).
Approximately 6 Fos-like immunoreactive neurones/section were seen in rats pre-treated with
the antagonist and followed with treatment of GHRP-6. It was 54.9 %, non-significantly,
higher than that of control rats. The Fos-like immunoreactivity of this group was attenuated by
63.0 % compared to that of rats pre-treated with Y1 and followed with saline treatment. The
total amount of Fos-like immunoreactive neurones induced by various treatments were shown
in fig. 3.3B. Overall, a significant increase in Fos-like immunoreactivity in the ventromedial
hypothalamic nucleus was seen only in rats pre-treated with Y1 receptor antagonist and





















Fig. 3.3. Fos protein induction in the ventromedial hypothalamic nucleus. (A)
Representative photomicrographs showing Fos immunoreactivity observed in the
ventromedial hypothalamic nucleus of rats. (B) Number of Fos-positive neurones in the
ventromedial hypothalamic nucleus. Rats were pre-treated (i.c.v.) and treated (i.v.) as
indicated. All data are the mean ± SEM (n = 6 in each group). Statistical significance of
differences comparedwith aCSF/Veh group: *-p<0.05 (Post-hoc t-test)
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3.6 Discussion
The results demonstrate a significant induction of Fos-like immunoreactivity in the arcuate
nucleus of rats injected (i.v.) with GHRP-6, consistent with previous reports (Dickson et al.,
1996). Previously, i.c.v. injection of GHRP-6 was also found to induce Fos-like
immunoreactivity in the arcuate nucleus (Dickson et al., 1995b). The distribution of Fos
staining in these different studies was generally very similar to the data described here, and in
particular, no other surrounding brain area was found to respond to GHRP-6, as measured by
Fos induction. The present results also show that, in the arcuate nucleus, pre-treatment with
NPY significantly attenuates the effects of GHRP-6 on Fos induction. This result is fully
consistent with the electrophysiological study of chapter 2, which showed that NPY is
predominantly inhibitory to arcuate neurones that are responsive to GHS. Thus the
electrophysiological findings and the immunohistochemical findings when taken together,
support the view that Fos is a reliable indicator of electrical activation in the arcuate nucleus.
Also as shown previously (Dickson et al., 1995b), administration of GHRP-6 did not induce
significant Fos expression in the ventromedial hypothalamic nucleus. As shown in chapter 2,
this brain region showed equally strong excitatory response to administration of both L-
144,446 or GHRP-6 in brain slice extracellular recording, To explain this discrepancy, it was
hypothesised that, in vivo, GHRP-6 administration leads to indirect inhibition of ventromedial
hypothalamic neurones by stimulating NPY neurones in the arcuate nucleus that project to the
ventromedial hypothalamic nucleus.
To investigate this hypothesis, the NPY Y1 receptor antagonist, L-753044-001J003, was
applied to rats before treatment with either saline or GHRP-6. A marked increase in Fos-like
immunoreactivity was seen in the ventromedial hypothalamic nucleus of rats followed the Y1
antagonist pre-treatment in saline-treated rats, and no increase was seen in the arcuate nucleus.
This indicates the existence of NPY inhibitory inputs to the ventromedial hypothalamic
nucleus that are tonically active in vivo, and demonstrate that neurones in this hypothalamic
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region do possess the intracellular machinery necessary for the induction of expression of Fos
protein.
In the arcuate nucleus, NPY Y1 receptor antagonist, when pre-treated to the rats that received
saline treatment later, caused a 36.7 % and non-significant increase in Fos-like
immunoreactivity compared to control group. This might suggest an existence of weak
spontaneous NPY inhibition in this brain region. Though, it remains unclear whether such NPY
inhibition is regulated by NPY neurones in the arcuate nucleus itself as autoregulation or by
presynaptic neurones from other brain regions.
In comparison, treatment with GHRP-6 in Y1 antagonist pre-treated rats caused a large
increase (315.8 % increase over control level) in Fos-like immunoreactivity in the arcuate
nucleus, but only a small increase (35.4 % increase) in the ventromedial hypothalamic nucleus.
This indicates that treatment with GHRP-6 has an inhibitory effect on neurones in the
ventromedial hypothalamic nucleus in vivo, in contrast to the direct excitatory effect of GHS




NPY mRNA EXPRESSION IN THE ARCUATE NUCLEUS IN
RESPONSE TO FOOD RESTRICTION AND CHRONIC




Since ghrelin was identified, its effects on feeding have been widely studied. Both i.c.v. and
i.p. administration of ghrelin increased feeding in freely feeding rats (Wren et ah, 2000). The
lowest doses of ghrelin that produced a significant stimulation of feeding were 1 nM and 30
pM after i.p. injection and microinjection to the arcuate nucleus of rats respectively (Wren et
ah, 2001). These doses were considered to be very low, as the plasma ghrelin concentration
after i.p. injection of 1 nM ghrelin was not significantly different from that occurring after a
24-h fast. Stimulated feeding by injection of ghrelin once a day for 7 days was associated with
a significant increase in body weight by days 6 and 7 (Wren et ah, 2001). This tends to suggest
reduced energy expenditure in ghrelin-treated rats.
There is evidence that the orexigenic effect of ghrelin is mediated via NPY. Co-localisation of
the GHS receptor and NPY mRNA has been reported in the rat arcuate nucleus (Willesen et ah,
1999) and ghrelin-induced feeding is abolished by i.c.v. administration of anti-NPY IgG 4 h
before ghrelin administration (Nakazato et ah, 2001). In the same study, ghrelin-induced
feeding was also suppressed by treatment with anti-AGRP IgG. In another study, treatment
with a single i.c.v. injection of ghrelin (500 ng/rat) increased NPY mRNA expression in the
arcuate nucleus by 160 % relative to vehicle-treated rats (Shintani et ah, 2001).
The previous chapters have shown that NPY is a potent inhibitor of electrical activity in the
ventromedial hypothalamic nucleus, which is a satiety centre, and have explored the hypothesis
that GH secretagogues activate an inhibitoryNPY input from the arcuate nucleus to this region.
The evidence that acute administration of GH secretagogues activates NPY neurones in the
arcuate nucleus is strong, but chronic central infusion of GH secretagogues does not lead to a
persistent activation of NPY mRNA expression in this region (Bailey et ah, 1999a). Central
administration of ghrelin for 3 days significantly increased the expression of both NPY and
agouti-related peptide (AGRP) mRNA expression in the rat arcuate nucleus (Kamegai et ah,
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2001b), but no increase has been seen with longer infusions of GH secretagogues (Bailey et al.,
1999a), although changes in appetite and weight gain persist.
Chronic infusions of GH secretagogues also lead to maintained increases in GH secretion and
growth rate, through actions both at the pituitary and on GHRH neurones (see Introduction).
However, chronic GH secretagogue treatment does not produce a sustained increase in GHRH
mRNA expression (Bailey et al., 1999a). Instead, paradoxically, it produces a sustained
increase in somatostatin mRNA expression in the periventricular nucleus. The likely
explanation is that the enhancement ofGH secretion, following GHS action at the pituitary and
on GHRH neurones, leads to enhanced activity of somatostatin neurones as a result of GH
feedback, which in turn results in somatostatinergic inhibition of GHRH neurones (see
Introduction), and this opposes the excitatory drive by GH secretagogues. Thus, in rats treated
with GH secretagogues there are normal levels of GHRH mRNA despite hyperactivation of
somatostatin neurones, reflecting continued excitation of GHRH neurones by GH
secretagogues.
The absence of a sustained change in NPY mRNA expression may have a similar explanation.
If activation of NPY neurones increases appetite, rats eat more, and hence satiety signals
increase. If satiety signals in turn inhibit NPY neurones, then we may expect to see little
overall change in NPY expression.
In this chapter we test this hypothesis. We treated rats chronically with i.c.v. GHRP-6, and
observed food intake, weight gain, and measured NPY mRNA expression in the arcuate
nucleus. Half of the rats were given free access to food; half were put on a restricted diet.
These rats were not allowed therefore to eat more than the control group during GHRP-6
infusion. We expected to find no change in NPY mRNA expression in the ad-lib fed GHRP-6-
treated rats. We expected also to find an increase in NPY mRNA expression in the food
restricted groups, reflecting hunger due to the food restriction. In rats, food restriction during
lactation, when demand for stored energy reserves is high, results in markedly increased NPY
mRNA expression in the hypothalamus (Wilding et al., 1997). Conversely, NPY mRNA
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expression in the arcuate nucleus is reduced in rats fed with high-fat diet (Stricker-Krongrad et
al., 1998).
4.2 Aims
This study was aimed to investigate sensitivity of arcuate neurones to food restriction and
chronic treatment of GHRP-6 in level ofNPY mRNA expression. The aim was also to examine
whether there is additive effect of food restriction and chronic treatment of GHRP-6 in rats
maintained under combination of both factors. In these rats, we expected to find a larger
increase in NPY mRNA expression in the GHRP-6-treated food restricted group, reflecting an
increase in appetite induced by the secretagogue.
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4.3 Methods
4.3.1 Animals and surgical implantation
Adult male Sprague Dawley rats (250-350 g) were maintained in a controlled environment (12
h light: 12 h dark, 21-23 °C) with free access to food and water. All surgical procedures were
carried out under a Home Office Project and Personal License. Experiment was performed
during the light cycle. Rats were anaesthetised with halothane (5 % halothane in a O2/NO2
mixture) and placed in a stereotaxic frame. An osmotic minipump (ALZA Corporation, USA)
filled with either 0.2 ml of GHRP-6 (1 pg/pl) or an equal volume of aCSF as vehicle, was
attached with a catheter and a guide cannula. Each rat was given either GHRP-6 or vehicle via
the osmotic minipump pump. The pump was placed under the body skin of the rat. Either
GHRP-6 or vehicle filled inside the pump was delivered through the catheter and the guide
cannula to the right lateral ventricle (co-ordinates: 3.0 mm posterior, 2 mm lateral of bregma,
0.1 mm from the surface of the skull) at 1.0 pl/h for 7 days. The needle was held in place with
dental acrylic bonded to stainless steel screws anchored to the skull. After the implantation, rats
were housed and maintained individually in stainless steel cages.
Rats implanted with GHRP-6 were divided into two groups: GHRP-6/ad libitum and GHRP-
6/food restricted (n = 7 each). Rats implanted with aCSF were also divided into vehicle/ad
libitum and vehicle/food restricted (n - 6 each). The group of vehicldad libitum fed rats was
taken as the control group. During the 7-day period of recovery, GHRP-6/food restricted and
vehicle/food restricted groups were given free access to water but limited access to pelleted
food (from 9.00 to 11.00 am each day). The groups of GHRP-6/W libitum and vehicldad
libitum were given food and water freely 24 h a day. All rats were handled daily to minimize
stressed-related effects while measuring body weights and the amounts of consumed food and
water.
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On the day of the experiment, rats had received a 7-day central infusion of GHRP-6 or aCSF.
They were quickly killed by using a guillotine, and brains were immediately removed, frozen
on dry ice and stored at -70 °C until in situ hybridisation was performed. Coronal brain
sections through the hypothalamus were cut at -16 °C on a cryostat at 15 pm thickness.
Sections were collected on RNAase-free gelatinised slides and stored in desiccated slide boxes
at -70 °C before undergoing in situ hybridisation. Every third section through the
hypothalamus was collected and counterstained with toluidine blue and coverslipped with
permount. These sections were later used as marker sections to confirm the location of areas of
interest on the section after in situ hybridisation.
4.3.2 Probe preparation
An oligonucleotide probe (NPY, MWG, Germany) was synthesised to correspond to
previously tested sequences. The probe sequences were complementary to the nucleotides
spanning the rat NPY (30-mer) coding region:, bases 5'-GGA GTA GTA TCT GGC CAT
GTC CTC TGC TGG-3' with GC content of 56.7 %. The lyophilised probes were reconstituted
using sterile double distilled water to a stock concentration of 100 pmol/pl. On the day of
labelling, the stock solution was further diluted to give a working solution of 10 pmol/pl. The
probes were thereafter 3' end-labelled using terminal deoxynucleotidyl transferase (Roche
Diagnostics, Germany) and 35S dATP (ICN, France) to a specific activity of 832115 cpm/pmol
in the final hybridisation mixture. They were finally purified and counted using a (3-counter.
4.3.3 In situ hybridisation
Selected slides of hypothalamic sections were left to warm up to room temperature. They were
then fixed in 4 % paraformaldehyde in 0.1 M phosphate buffer (pH 7.2) for 10 min and washed
twice with 0.1 M phosphate buffer saline (5 min each). After that, they were acetylated with a
solution containing 0.25 % acetic anhydride, 0.1 M triethanolamine (TEA) and 0.9 % NaCl to
reduce non-specific DNA binding to charged particles, and rinsed twice with sterile double
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distilled water (2 min each). Sections were dehydrated through a series of ethanol solutions (70
%, 95 % and 100 %), delipidated with 100 % chloroform (CHCI3) to improve probe access,
followed by rehydration in ethanol solutions (100 % and 95 %). Slides were then air-dried
thoroughly.
Dried sections were hybridised in the following buffer: for 1.0 ml, 100 pi working solution of
probe, 450 pi hybridisation buffer (see solution preparation), 450 pi formamide and 10 pi
dithiothreitol (DTT). For a pair of brain sections on one slide, 45 pi of hybridisation mixture
was required. Nescofilm coverslips were used to cover the sections to ensure that the mixture
was evenly distributed across the tissue and that no air bubbles were trapped. Hybridisation
was carried out in a moist chamber for overnight at 37 °C. Hybridised slides were then dipped
briefly in 3 washes of lx standard sodium citrate (SSC: 0.0075 M NaCl and 15.0 M tri-sodium
citrate) at room temperature to remove the nescofilm and to wash out excess unhybridised
probes. Next, they were washed with lx SSC at 55°C in a water bath for 4 x 15 min, then with
lx SSC at room temperature twice (30 min each). Finally, slides were rinsed briefly twice with
double distilled water at room temperature, and left to dry in an incubator.
The following processes were performed in darkness. Dried slides were arranged onto plastic
holders and dipped in autoradiographic emulsion that was freshly prepared by diluting
emulsion (Kodak, G5 Ilford, UK) with warm water (ratio 3:1). They were dried overnight, then
kept in sealed plastic boxes and stored at 4 °C for 3 weeks.
Autoradiographic silver grains of hypothalamic sections of test slides were roughly checked
whether the reaction period was optimum. When satisfied, the rest of the slides were placed in
racks. They were dipped in developer solution for 5 minutes, double distilled water for 2 s,
fixer I and II for 5 min each, and finally washed with double distilled twice for 5 min each.
Then slides were air-dried thoroughly.
Sections were counterstained by running through the haematoxylin and eosin solutions (see




Hybridisation signals were quantified by using a computer image analysis programme, NIH
image. Sampling was done bilaterally in the arcuate nucleus with the x5 and x20 objectives.
Relative amount ofNPY mRNA in the arcuate nucleus was assessed by the silver grain density
of autoradiographic emulsion dipped slides. Autoradiographic grains were viewed under light
microscope attached to a high performance CCD video camera (Cohu). Signal was displayed
in dark-field image. Silver grains in the arcuate nucleus and the background, and unit area of
measurements, were quantified and digitised by NIH Image analysis system version 1.58 on an
Apple Mcintosh computer. The NIH-Image public domain image processing software package
was developed by Wayne Rashband. Using the x5 objective, a cell was considered to be
positive when it contained more than 3 times the background number of silver grains. The
average number of silver grain per cell was measured using the x20 objective, for each cell.
The value of silver grain density per unit area was obtained by subtracting the mean silver
grain area of the background measurements from each specific nucleus measurement, and
divided by the area measurements. A total of 5 positive NPY mRNA-containing cells was
counted for each side of the arcuate nucleus. The mean average silver grain per unit area was
calculated for each arcuate nucleus. Mean silver grains per unit area was then calculated for
each area of the arcuate nucleus (A, B, C, D and A-D is whole arcuate nucleus), and finally the
mean value per rat and group means were calculated. Group means for all areas and groups
were compared statistically using Two-way ANOVA (Student-Newman Keuls Method).
4.5 Materials and solution preparation
Gelatine coated slides
Slides (super premium twin-frost; BDH 406/0181/04) were washed in chromic acid overnight.
The next day, the slides were rinsed in cold running tap water for approximately 2 h until the
slides were completely rinsed. The slides were then passed through three changes of a dd^O
and once in DEPC-treated water. After that, the slides were immersed in 80 % alcohol [400 ml
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absolute (100 %) ethanol + 100 ml DEPC ddH20] and dried in the 60°C oven. Once the slides
were dry, they were removed from the oven, and allowed to cool to room temperature. Next,
the slides were subbed in chrome-alum/gelatine solution and drain on paper towelling. They
were subbed in gelatine again after they were dry.
Solution preparation
Chromic acid
For 2000 ml final volume, 200 g potassium dichromate was added to 2000 ml. Concentrated
sulphuric acid (20 ml) was slowly added to the flask whilst it was immersed in cold water (to
cool exothermic reaction).
Diethyl pyrocarbonate treated water (DEPC-treated water)
One ml of diethyl pyrocarbonate (Sigma) was added to 1000 ml of ddH20 in a bottled. The
bottled was shaken vigorously for 2 min, allowed to stand for 1 h, and then autoclaved.
Chrome alum gelatine subbing solution
A beaker containing 800 ml ddH20 was heated in a microwave to 70°C. Gelatine powder (2.25
g) was added to the heated water on a magnetic stirrer. After this dissolved and the solution had
cooled down, 0.23 g chromic potassium sulphate was added on stirrer.
Tissue fixation solutions
1.0Mphosphate buffer saline (PBS, pH 7.2-7.4)
Amount and final concentration of chemicals for a final volume of 1000 ml
115.0 g Disodium hydrogen orthophosphate 2-hydrate 11.5% w/v
27.2 Sodium dihydrogen orthophosphate 1-hydrate 2.72 % w/v
These two chemicals were dissolved in 800 ml DEPC-treated ddH20 and then made up to 1000
ml. The solution was adjusted to pH 7.2-7.4 with 1 M NaOH. More dilute solutions were made
by diluting this PBS stock with DEPC-treated ddH20
4 % paraformaldehyde (PFA) in 0.1 M PBS (pH 7.4)
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Firstly, 8 % of PFA was made by adding PFA to 80°C ddH20. The solution was then adjusted
to pH 7.4 with 1 M NaOH. Finally an equal volume of 0.2 M PBS was added to make a final
solution with 4 % PFA in 0.1 M PBS. The solution was chilled in a fridge before use.
Triethanolamine (TEA)Zacetic anhydride solution
Triethanolamine solution was made in ddH20, containing 1.48 % v/v TEA, 0.25 % v/v acetic
anhydride and 0.42 % v/v concentrated hydrochloric acid or 0.9 % w/v NaCl.
Probe labelling method
The following components were put into a sterile Eppendorf tube.
27 pi sterile ddH20
10 pi 5xTdT tailing buffer
5 pi 2.5 mM Cobalt chloride (CoCl2)
5 pi 35S dATP
2 pi probe (working dilution 10 pmol/ pi)
Then 1 pi TdT enzyme (25 units/ pi) was added to start the reaction. The mixture was mixed
well using a Gilson pipette. The Eppendorf was put into a polystyrene holder and allowed to
float in the water bath (37°C) for 1 h. After 1 h, the Eppendorf was removed from the water




5 M NaCl (292 mg/ml)





EDTA 250 mM (232.6 mg/ml) 400 pi (dissolved in hot water) RT
Dextran sulphate 25 %
NaPPI 5 % (50 mg/ml)








Yeast total RNA (20 mg/ml)
Salmon testes DNA (10 mg/ml)
250 pi (boiling water 10 min) -20°C










*Denhardt's solution was made with:
BSA 1.6% (200 mg/ml) 4°C
Ficoll 6 % (100 mg/ml) 4°C
PVP 6% (100 mg/ml) RT
Preparation of hybridisation buffer components
5 MSodium chloride
For a final volume of 50 ml, 14.6 g NaCl was added to 45 ml sterile ddH20 in sterile falcon
tube and dissolved. The volume was made up to 50 with sterile ddH20. Then, the solution was
added with 50 pi DEPC, and shaken vigorously. The solution was left for 1 h and then
autoclaved. The solution was aliquoted into sterile 2-ml Eppendorfs and stored at -20°C.
TrispH 7.6
For a final volume of 20 ml, 20 ml sterile ddH20 was put into a sterile falcon tube. It was
added with 2.98 g Trizma base. The solution was adjusted to pH 7.6, aliquoted into sterile 1-ml
Eppendorfs, and stored at room temperature.
Denhardt's solution
For a final volume of 50 ml, 0.5 g ficoll and 0.5 polyvinylpyrrolidone were added to 40 ml
DEPC-treated water in a sterile falcon tube and mixed well. Then 1 g BSA was added and
mixed gently. The solution was made up to 50 ml with DEPC-treated water, and filtered
through a 0.2 pm Acrodisk filter. The solution was dispensed into 1 ml aliquots in 2-ml sterile
Eppendorfs and stored at -20°C.
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EDTA 250 mM
EDTA (23.26 g) was added to 250 ml of sterile ddH20. The solution was adjusted to pH 8.0
with NaOH, and autoclaved in 250 ml Duran. It was dispensed into 400 pi aliquots.
Dextran sulphate
Dextran sulphate (12.5 g) was added to 15 ml of DEPC-treated water. The solution was mixed
and warmed at 50 % for about 4 h. Then, it was made up to 25 ml with DEPC-treated water
and stored at 4°C.
Sodium pyrophosphate (NAPPI)
NaPPI (0.5 g) was dissolved with 10 ml sterile ddH20, and aliquoted into sterile Eppendorfs
(400 pi each). The aliquots were stored at room temperature.
Yeast tRNA
Yeast tRNA (100 mg) was put into a sterile 50 ml falcon tube. Then, 4 ml DEPC-treated water
was added and mixed well. The solution was aliquoted into sterile 200-ul Eppendorfs and
frozen at -20°C.
Yeast total RNA
Yeast total RNA (60 mg) was dissolved in 3 ml of DEPC-treated water, and aliquoted into
sterile 250-pl Eppendorfs. The aliquots were stored at -20°C. When needed for making up the
hybridisation buffer, a 250-pl aliquot was boiled for 10 min before hybridisation buffer was
made.
Salmon testes DNA
Salmon testes DNA (50 mg) was added to 5 ml DEPC-treated water in tube, and agitated for 2
h. Mixture was sheared by passing through a sterile 19-gauge needle for eight times. The tube
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was placed into a beaker of boiling water for 5 min, and cooled to room temperature. After
that, it was aliquoted (1 ml each), and stored at 4°C.
Poly (A)
Fifteen mg of poly (A) was added to 1 ml DEPC-treated water and aliquoted into 330-pl
Eppendorfs.
Formamide (50 %>)
Twenty-five ml of 100 % stock was used per 50 ml hybridisation buffer.
1.0 MDithiothreitol (DTT)
DTT (154 mg) was added to 1 ml of DEPC-treated water. The solution was left for 30 min and
filtered through an acrodisk. It was aliquoted into sterile 50-pl Eppendorfs, and stored at -20°C.
DTT was not added to the hybridisation buffer until the day of use.
Post hybridisation washes
2Ox standard sodium citrate (SSC) stock solution
Amount and final concentration of chemicals for 1000 ml
175.4 g Sodium chloride 17.54 % w/v
88.2 g tri-sodium citrate 8.82 % w/v
This stock solution was used for making diluted SSC solution by diluting with ddH20.
Counterstaining
Haematoxylin and eosin solutions
Harris' Haematoxylin:
Amount of chemicals for approximately 230 ml
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1 g Haematoxylin
10ml absolute alcohol
20 g ammonium or potassium alum (aluminium sulphate)
200 ml distilled water
0.5 g mercuric oxide
8 ml glacial acetic acid
Method
A) Dissolve haematoxylin in the alcohol and add to the alum (previously dissolved in
hot water)
B) Bring quickly to the boil and add the mercuric oxide, when the solution will turn
dark purple
C) Cool rapidly under the tap, filter before use
D) Add glacial acetic to sharpen the nuclear staining
Make up in the fume cupboard, using a flask of ample size on account of the frothing that takes
place on the addition of the mercuric oxide
1 % Eosin
Dissolve 1 g eosin in 100 ml distilled water
Scott's Tap Water Substitute-STWS
For 1000 ml, dissolve 20 g magnesium sulphate and 3.5 g sodium bicarbonate (sodium
hydrogen carbonate) in 1000 distilled water.
5 % Potassium Alum
For 100 ml, dissolve 5 g aluminium potassium sulphate or potassium aluminium sulphate in
100 ml distilled water.
1 % Acid Alcohol
For approximately 1000 ml, add 700 ml 740P or IMS alcohol with 300 ml distilled water.
Finally, add 10 ml hydrochloric acid (cone).
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Haematoxylin and Eosin Staining
Method
Run slides through the following solution.





(lithium carbonate in 70 % if needed to remove Bouin's)
Wash in running water
Dip in acid alcohol (if needed to differentiate)
Wash in running water
STWS 3 min
Water 3 min
Eosin (filter before use) 2 min
(check staining under microscope)
Dip in running water
Potassium alum 2 min








Coverslip using DPX mountant
Results 139
4.6 Results
4.6.1 Effect of chronic administration of GHRP-6 on food and water intake
The effect of central administration of GHRP-6 was examined in rats implanted with chronic
i.c.v. cannula and minipump. Two groups of rats were given food and water ad libitum, and
two groups were given food for only 2h per day, (food restriction group). For each feeding
regime, rats were centrally infused with either GHRP-6 (1 pg/(il/h) or 0.9 % saline.
All rats given food restriction ate only a few grams on the first day after surgery (data not
shown), probably because they were naive to the condition that food was going to be removed
after 2-h. On this first day after surgery, all rats received vehicle i.c.v. By day 2, the food intake
of all rats increased up to approximately 6 and 8 g in saline and GHRP-6 groups respectively.
Thus, analysis of the effects ofGHRP-6 on food and water intake and body weight of rats were
analysed from day 2 of the experiment.
In ad libitum fed rats, rats given saline showed no consistent variation in food intake
throughout the 6 days of the experiment. However, rats given GHRP-6 showed a higher food
intake on day 5 and day 6 than vehicle-treated rats (fig. 4.1A). On day 5, the GHRP-6 group
showed an average food intake at 32.7 g, compared to 25.2 g consumed by control rats.
Statistical analysis showed a significant effect of GHRP-6 treatment on food intake on day 5
and day 6 of the experiment (one way repeated measures ANOVA; p = 0.05). When the
amount of food intake was analysed as cumulative food intake over 6 days, the GHRP-6 group
ate 17.7 g more than the control group (t-test, /?<0.05) (fig. 4.1C)
In food restricted groups, food intake was similar on day 2 in saline and GHRP-6 groups (fig.
4.1B). Thereafter, average food intake gradually increased up to day 6 in both groups.
Statistical analysis showed no significant differences between saline and GHRP-6 groups on
any day of the experiment (Two-way ANOVA, /?=0.05). Overall, increase in food intake in
both saline and GHRP-6 groups was dependent on duration of food restriction, but not on
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GHRP-6 treatment. When analysed as cumulative food intake over 6 days, the GHRP-6 group
ate 4.5 g more than the saline group (not significantly different; fig. 4.ID)
Effects of feeding regime {ad libitum and food restriction) and effects of treatment (saline and
GHRP-6), on food intake, were determined statistically. Two-way ANOVA revealed that food
restriction, but not type of treatment, had a significant influence on amount of food intake
{p<0.05, Student-Newman-Keuls Method). This was reflected by relatively equal amount of
food intake seen in saline and GHRP-6 groups of each day ofboth feeding regimes.
The water intake in the above rats was also measured. Like food intake, water intake of rats on
a restricted diet was almost completely absent on day 1, and then had returned to average level
on day 2 with about 33 ml ofwater intake in rats of both feeding regimes. Thereafter, the water
intake of rats fed ad libitum in saline group during the first 5 days was relatively stable, but
increased on day 6 after surgery (fig. 4.2A). In the GHRP-6 group, water intake was significant
increased on day 4 and day 5, compared to saline group (One-way repeated measures ANOVA,
/?=0.05). The cumulative water intake over 6 days was 14.1 % significantly higher in GHRP-6
treated rats than in the saline-treated rats (t-test, p<0.05; fig. 4.2C)
In food-restricted rats given either saline or GHRP-6, water intake slightly decreased from day
2 to day 4 but was rather stable thereafter. In food-restricted rats, GHRP-6 group showed non-
significantly higher water intake than the saline group on day 2 and day 3, but after that both
groups showed relatively equal volume of water intake (Two-way ANOVA, p=0.05). No
significant difference between saline and GHRP-6 groups of rats maintained on a feeding
restricted diet was seen, even when expressed as cumulative water intake over 6 days (t-test,
p=0.05; fig. 4.2D).
However, statistic analysis revealed that the feeding regime had significant influence on water
intake, whereas GHRP-6 treatment did not significantly influence water intake (Two-way

























2 3 4 5 6
Day after surgery
Fig. 4.1. Effectof i.c.v. injection ofGHRP-6 or saline on food intake. Effects ofsaline (0.9%
saline: white, n = 6) and GHRP-6 (1 pg/pl/h: black, n=7) on food intake ofrats thatwere fed
ad libitum (A) and maintained on a restricted feeding diet (B) were illustrated. Data were
also expressed as cumulative food intake (C: ad libitum and D: restricted feeding diet).
Error bars are SEM. Statistical significance ofdifferences between groups: * =p<0.05, (for






















































2 3 4 5 6
Days after surgery
Fig. 4.2. Effect of i.e.v. injection ofGHRP-6 or saline on water intake. Effects of saline (0.9 %
saline: white, n- 6) and GHRP-6 (1 pg/pl/h: black, n=7) on water intake ofrats that were fed ad
libitum (A) and maintained on a restricted feeding diet (B) were illustrated. Data were also
expressed as cumulative water intake (C: ad libitum and D: restricted feeding diet). Error bars
are SEM. Statistical significance of differences between groups: * — p<0.05, (Repeated
measures, one-way ANOVA, Student-Newman-Keuls Method for daily water intake and t-test
for cumulativewater intake).
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4.6.2 Effect of chronic administration of GHRP-6 on rat body weight
In rats receiving food ad libitum, i.e.v. infusion of GHRP-6 (1 mg/ml/h) caused an
approximately 3-fold greater daily weight gain measured on day 2 after surgery, compared to
rats given i.c.v. saline infusion : saline group showed daily weight gain about 3 g while GHRP-
6 showed about 11 g (fig. 4.3A). Thereafter, the daily weight gain of GHRP-6 treated rats was
higher on each day than in the saline group. Data were also expressed as cumulative body
weight gain over 6 days of experiment (fig. 4.3C). When expressed as cumulative body weight
gain, the GHRP-6 group showed significant differences in cumulative body weight change
relative to the saline group over 5 and 6 days (t-tests, p<0.05,).
In rats maintained on a restricted feeding diet, both saline and GHRP-6 groups showed a large
decrease in body weight on day 2 (fig. 4.3B). Rats in the saline group lost about 20 g, whereas
GHRP-6-treated rats lost about 25 g. However, from day 3 to day 6, the magnitude of daily
weight loss was reduced to about 5 to 10 g per day for both saline and GHRP-6 groups.
Overall, rats given either saline or GHRP-6 showed similar patterns of daily weight change.
The cumulative weight loss of the GHRP-6 group was significantly less (18.9 %) than that of
saline group over 6 days (t-test, p<0.05) (fig. 4.3D).
Altogether, statistical analysis of the body weight of rats on a restricted feeding diet revealed
that daily weight change was dependent on length of time after the start of food restriction, but





























































2 3 4 5 6
Days after surgery
Fig.4.3 . Effect of i.c.v. injection of GHRP-6 or saline on body weight change. Effects of
saline (0.9 % saline: white, n = 6) and GHRP-6 (1 pg/pl/h: black, n = 7) on body weight
change of rats that were fed ad libitum (A) and maintained on a restricted feeding diet (B)
were illustrated. Data were also expressed as cumulative weight change (C: ad libitum and
D: restricted feeding diet). Error bars are SEM. Statistical significance of differences
between groups: * = p<0.05, (Repeated measures, one-way ANOVA for daily weight
change and t-test for cumulativeweight change).
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4.6.3 Effects of food restriction and chronic administration of GHRP-6 on
expression of NPY mRNA in the arcuate nucleus
Light microscopic examination of coronal section taken through the rat brain, revealed
autoradiographic NPY mRNA hybridisation signal in hypothalamic brain slices (fig. 4.4). The
number of neurones labelled with silver grains in 4 areas located rostro-caudally from area A to
D in the arcuate nucleus was counted and analysed. Basal expression ofNPY transcripts within
the arcuate nucleus was examined in rats fed ad libitum and receiving chronic vehicle infusion.
In these rats, the average number of NPY mRNA hybridising neurones in the arcuate nucleus
varied from about 32.4 ± 45.8 /arcuate nucleus/section (area A) to 270.7 ± 82.2 /arcuate
nucleus/section (area C), with an average of 149 ± 52.3/arcuate nucleus/section for all 4 areas
(fig. 4.5A).
In rats fed ad libitum and receiving chronic infusion of GHRP-6, the arcuate nucleus showed a
relatively even distribution of NPY mRNA expression throughout the arcuate nucleus. The
average number of positive neurones varied from 83 ± 65.1 to 181.0 ± 98.3 with an average of
172.5 ±71.9 for all 4 areas. The NPY mRNA expression of this group was not significantly
different from the control group (t-test,/?>0.05).
Intensely labelled neurones were substantially detected in the arcuate nucleus of rats
maintained on a restricted feeding diet. In rats receiving chronic infusion of vehicle, the
number of NPY mRNA hybridising neurones was 405.2 ± 139.3 in area B. Overall, the total
average number of positive neurones of this group was 350.6 ± 77.0, 96.1 % higher than in
control group. The arcuate nucleus of rats maintained on the same feeding regime but receiving
chronic infusion of GHRP-6 showed the average number of positive neurones for all 4 regions
of 234.0 ± 39.3 which was non-significantly higher than those in both groups of rats fed ad
libitum, but lower than that of rats treated with chronic saline and feeding restricted diet (Two-
way ANOVA, />>0.05).
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Data of NPY mRNA expression in the arcuate nucleus of rats maintained on either feeding
regimes and combined with treatment of either vehicle or GHRP-6 were analysed statistically.
Two-way ANOVA test revealed that food restriction had a significant influence in inducing
NPY mRNA expression, where as ad libitum feeding regime and GHRP-6 chronic
administration did not (Two-way ANOVA, Student-Newman-Keuls Method, p<0.05).
Data were also expressed as total silver grains per arcuate nucleus (fig. 4.5B). Both groups of
rats maintained on a feeding restricted diet showed high number of total silver grains than both
groups of rats fed ad libitum. The average number of positive neurones of all 4 areas of the
arcuate nucleus of 4 groups is shown in fig. 4.5C.
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Fig. 4.4. Effect of feeding regimes and chronic i.c.v. administration of GHRP-6 on NPY
mRNA expression in the arcuate nucleus of rats. Rats were fed and chronically infused as
indicated for 7 days. NPY mRNA levels in the arcuate nucleus were determined by in situ
hybridisation. Representative sections of the arcuate nucleus showing expression ofNPY
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Fig. 4.5. The number ofarcuate nucleus neurones expressingNPYmRNA, as detected by in
situ hybridisation. (A) Bar graph shows the total number ofpositive neurones per total area
ofarcuate nucleus. Rats were chronically infused (i.e.v.) with either saline (0.9 % saline) or
GHRP-6 (1 pg/pl/h), and maintained either on ad libitum or a restricted feeding diet for 7
days. The total number of positive neurones per arcuate nucleus is shown in 4 parts of the
arcuate nucleus; A, B, C, and D (from the anterior to posterior). A: 1.8- 2.3 mm, B: 2.3 - 2.8
mm, C: 2.8 - 3.3 mm, D: 3.3 - 4.16 mm posterior to bregma. (B) The total amount of silver
grains ofpart B ofthe arcuate nucleus. (C) The average number ofpositive neurones per total
area of arcuate nucleus. All data are the mean ± SEM (n = 3-7 in each group). Statisticalt
significance ofdifferences comparedwith vehlad lib group: *=p<0.05 (Two-way ANOVA)
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4.7 Discussion
Orexigenic effects of GHSs on food intake in rats have been well-documented, and it has been
hypothesised that these orexigenic effects are mediated via NPY pathway in the hypothalamus.
Our previous results of the electrophysiological experiments (chapter 2) showed convergence
between the actions of secretagogues and NPY in the arcuate nucleus and in the ventromedial
hypothalamic nucleus. Furthermore, our immunohistochemistry studies (chapter 3) revealed an
interaction between GHRP-6 and NPY in the arcuate nucleus. In previous studies studies,
induction of c-fos mRNA expression in NPY neurones of the arcuate nucleus has been
described following administration ofGHRP-6 (Dickson and Luckman, 1997).
In this experiment, significant effects of chronic administration ofGHRP-6 on cumulative food
and water intake were observed in rats fed ad libitum, compared to rats receiving chronic
administration of vehicle. However, as shown previously (Bailey et al), chronic treatment with
GHRP-6 had no significant effect on NPY mRNA expression in the arcuate nucleus. This does
not seem to be because our techniques were too insensitive to measure a change in NPY
mRNA expression because, again as reported previously, food-restricted rats showed a large
and significant increase in NPY mRNA expression.
It appeared possible that in rats given GHRP-6, the secretagogue caused an increase in food
intake through activation of NPY neurones, but that the increased food intake in turn resulted
in an increased inhibition of NPY cells reflecting stronger satiety signals, possibly through
increased leptin secretion. We therefore looked at the effects ofGHRP-6 infusion in conditions
where the rats were not able to increase their food intake. If the orexigenic effects of GHRP-6
are mediated by NPY neurones, we might expect in these circumstances to reveal a stimulatory
effect of GHRP-6 on NPY mRNA expression.
In food-restricted rats, as planned, GHRP-6 produced little increase in food intake compared
with vehicle-infused rats, and both GHRP-6 and vehicle-infused rats lost weight progressively
during the course of treatment. NPY mRNA expression was higher in both food-restricted
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groups than in the ad libitum fed groups, but the level of expression in the food restricted rats
treated with GHRP-6 was lower than in the food-restricted rats treated with vehicle. The
difference between groups was not significant, but clearly there was no increase in NPY
mRNA expression in response to GHRP-6.
At face value, these data suggest that, while increased hunger associated with food restriction is
associated with increased NPY mRNA expression in the arcuate nucleus, the increase in food
intake that follows chronic GHRP-6 treatment is not a consequence of increased activity in
NPY neurones.
Acutely, GHRP-6 does induce activity in NPY neurones of the arcuate nucleus. However,
GHRP-6 had no acute effect on food intake in these experiments. It should be remembered that
not all NPY neurones in the arcuate nucleus are necessarily involved in feeding. Only a subset
of these NPY neurones which project to the paraventricular nucleus have a clearly defined role
in feeding regulation, and few of these appear to be sensitive to GHRP-6. Most of the arcuate
neurones that are sensitive to GHRP-6 project to the median eminence, and their function
remains largely unknown.
It seems possible therefore that the effects of chronic GHRP-6 on food intake may be unrelated
to the actions of GHRP-6 in the arcuate nucleus. Is it possible that they are instead related to
the actions of GHRP-6 in the ventromedial hypothalamus? At this site, GHRP-6 has no effect
when given acutely in vivo, although the cells there express functional GHS receptors. I have
speculated that the reason why no acute response is seen in the ventromedial hypothalamus in
vivo may be because NPY released from arcuate neurones counteracts the stimulatory effects
of GHRP-6. However, studies of mRNA expression suggest that during chronic GHRP-6
treatment, the activation of NPY cells may be only transient. If the effects of GHS in the
ventromedial hypothalamus are sustained while the effects of NPY are transient, then this
might explain a delayed effect of chronic treatment on food intake, as observed in the present
experiments. However, a late activation of ventromedial hypothalamic neurones would be
expected to reduce feeding rather than to stimulate feeding.
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Clearly, there are many other pathways in the hypothalamus that are involved in the control of
feeding, and these may be indirectly affected by changes in the activity of either arcuate
neurones or ventromedial hypothalamic neurones. Future studies may need to focus on changes








The arcuate nucleus has been a major focus for numerous studies to clarify the mechanisms of
regulation of GH secretion. It has been consistently found to mediate effects of the class of
novel synthetic compounds termed GHSs. Many neurones in this brain area were previously
demonstrated to be NPY neurones (Willesen et al., 1999), and NPY synthesised in the arcuate
nucleus is associated with the regulation of feeding (Beck et al., 1990b), which is one recently
discovered action of GHS. Although some of the basic elements of this control system have
been identified, little is known about the mechanisms by which GHSs exert their effects on
feeding and GH secretion.
In this study, effects of secretagogues L-144,446 and GHRP-6 on electrophysiological activity
of arcuate neurones was studied using hypothalamic brain slices for extracellular recordings in
vitro. Significant excitatory effects of these secretagogues were observed, though not every
recording was tested whether these effects were direct but alteast some of them were shown to
be direct effects. In these experiments, the electrical activity of arcuate neurones was also
shown to be inhibited by both NPY and somatostatin. Interestingly, there was large proportion
of arcuate neurones that responded to both GHS and NPY. Thus, these results suggest the co-
expression of receptors for GHSs, NPY and somatostatin in the arcuate nucleus.
The effects of these compounds were also tested on neurones in the ventromedial hypothalamic
nucleus. This area was previously demonstrated to show dense expression of GHS-R mRNA in
the rat, though in the mouse the expression in the ventromedial hypothalamic nucleus is not as
dense as in the arcuate nucleus (Mitchell et al., 2001). Whereas systemic or central application
of GHS results in dense Fos expression in the arcuate nucleus of both rats and mice, similar
induction of dense Fos expression is not seen in the ventromedial hypothalamic nucleus.
Surprisingly, therefore, when tested in vitro, responses of ventromedial hypothalamic neurones
to GHRP-6 were very similar to those recorded in arcuate neurones. This finding confirmed the
existence of functional GHS receptors in the ventromedial hypothalamic nucleus, and indicated
that the GHS receptors in the ventromedial hypothalamic nucleus are coupled to electrical
excitation in a similar way to GHS receptors on neurones of the arcuate nucleus.
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According to significant response of ventromedial hypothalamic neurones to GHRP-6 in vitro,
but apparently not in vivo, it was hypothesised that these neurones were affected by inhibitory
inputs from nearby areas. Here, we showed that ventromedial hypothalamic neurones were also
inhibited by bath application of NPY or somatostatin in vitro. Since the arcuate nucleus is a
major source of NPY synthesis, we speculated that NPY or somatostatin was involved in
preventing ventromedial hypothalamic neurones from neuronal activation by GHSs in vivo.
Thereafter, the effects of GHRP-6 and NPY on neuronal activity of the arcuate nucleus and the
ventromedial hypothalamic nucleus were examined by using immunohistochemistry to detect
Fos induction as an indicator of cellular activation. As expected, arcuate neurones were
significantly excited by systemic administration of GHRP-6. Consistent with the in vitro
electrophysiological study, this excitation was significantly attenuated by central
administration of NPY. Previously, GHRP-6 and a non-peptide GH secretagogue, MP-0677,
were demonstrated to induce Fos protein in the arcuate nucleus of rats, and these effects were
also attenuated by central administration of somatostatin (Dickson et ah, 1997).
Also in this immunohistochemical study, Fos induction was observed in the ventromedial
hypothalamic nucleus after central administration of NPY Y1 receptor antagonist, L-753044-
001J003. Importantly, the ability to induce Fos expression in the ventromedial hypothalamic
nucleus shows that the intracellular pathways responsible for regulation of c-fos are present in
these neurones, hence the absence of Fos expression at this site after GHS does not simply
reflect an inability of these cells to express Fos. Furthermore, these results demonstrated that in
vivo there appears to be spontaneous or tonic NPY inhibition of ventromedial hypothalamic
neurones, and our electrophysiological studies showed that this was mediated at least in part by
Y1 receptors. However, in rats that were given a Y1 antagonist centrally and followed with
systemic injection of GHRP-6, no significant Fos induction was observed in this area. Thus it
appears that following GHRP-6 injections, there is active inhibition of neurones in the
ventromedial hypothalamic nucleus, and this inhibition is not wholly through Y1 receptors. It
is likely therefore that NPY is not the only inhibitory compound whose release in the
ventromedial hypothalamic nucleus is activated by GHRP-6, or that the Y1 receptor is not the
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only receptor through which NPY can inhibit neurones in the ventromedial hypothalamic
nucleus.
Since inhibitory effects of somatostatin were also detected in ventromedial hypothalamic
neurones in vitro, it is also possible that activation of somatostatin neurones by GHS may
counteract the excitatory effects of GHS in the ventromedial hypothalamus in vivo. In the
arcuate nucleus, Fos expression induced by GHRJP-6 is attenuated by exogenous administration
of somatostatin (Dickson et al., 1997). In the mouse, though not in the rat, systemic injection of
GHS induces Fos expression in the periventricular nucleus, probably in the neurosecretory
somatostatin neurones. By using a double-label in situ hybridisation, somatostatin neurones in
the periventricular nucleus of the hypothalamus were reported to co-express the GH receptor
mRNA (Burton et ah, 1992). Thus periventricular somatostatin neurones may be activated as a
result of the growth hormone release that follows administration of GHS. Exogenous growth
hormone attenuates GHS-induced Fos expression in the arcuate nucleus in mice, and this effect
is absent in transgenic mice that lack somatostatin SSTR2 receptors. Thus it seems likely that,
after GHS activation of GHRH neurones, growth hormone is released and feeds back upon
periventricular somatostatin neurones that in turn inhibit GHRH neurones (Zheng et ah, 1997).
In rats treated chronically with i.c.v. GHRP-6 there is a sustained up-regulation of somatostatin
mRNA expression in the periventricular nucleus, consistent with activation of somatostatin
release in the rat following GHS treatment (Bailey et ah, 1999a).
Whether periventricular somatostatin neurones regulate ventromedial hypothalamic neurones is
not known. There are also somatostatin cells in the arcuate nucleus, and this population
projects centrally rather than to the median eminence (Baker and Herkenham, 1995). In
previous studies, GHS-R mRNA expression was localised in 30 ± 6 % of arcuate neurones that
express somatostatin mRNA (Willesen et ah, 1999). However the arcuate somatostatin
neurones do not express Fos in response to systemic GHS (Dickson and Luckman, 1997), and
somatostatin mRNA expression in the arcuate nucleus, unlike that in the periventricular
nucleus, is unchanged following chronic i.c.v. infusion ofGHS (Bailey et ah, 1999a).
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In addition, it has been reported that a subpopulation of NPY-producing neurones in the
arcuate nucleus co-produces GABA (Horvath et al., 1997). Microinjection of either NPY or
muscimol, a GABAa receptor agonist, into the paraventricular nucleus stimulated food intake,
and co-injection of these compounds elicited a significantly higher response than that evoked
by either individual treatment (Pu et al., 1999). These findings suggest complementary actions
of co-released NPY and GABA in stimulation of feeding. Thus, it is possible that activation of
arcuate NPY neurones results in the co-release of NPY and GABA, and hence blocking NPY
actions alone does not eliminate their inhibitory effects on the ventromedial hypothalamic
nucleus.
According to accumulating evidence of NPY involvement in food intake, it was hypothesised
that NPY neurones in the arcuate nucleus are sensitive to food deprivation or prolonged
treatment of GHS. To investigate this question, we measured NPY mRNA expression in the
arcuate nucleus of rats after chronic central administration of GHRP-6. Previous studies have
shown no change in expression ofNPY mRNA under these conditions, which seems surprising
given the acute effects of GHS on NPY neurones, and given the effects of chronic GHS on
food intake which seems therefore likely to be mediated by activation of NPY neurones.
However it seemed possible that GHS produced an increased excitation of NPY neurones,
leading to increased food intake, leading to increased satiety signals, leading in turn to
inhibition of NPY neurones. We therefore looked at the effects of chronic GHS in conditions
where the treated rats were not allowed to increase their food intake. The results of this
experiment showed that as shown previously, chronic GHRP-6 had no significant effect on
NPY mRNA expression in ad lib fed rats, despite producing an increase in food intake and
body weight. Furthermore, food restriction produced, as expected, a significant increase in
NPY mRNA expression, demonstrating our ability to measure an increase NPY mRNA
expression by our techniques. However, in food restricted rats, chronic treatment with GHRP-6
produced no further increase in NPY expression above vehicle controls. Thus the increased
food intake in rats treated chronically with GHS is not accompanied by increased expression of
NPY mRNA, even in conditions where the rats are unable to satisfy an increased hunger drive
by eating.
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Although NPY cells that project from the arcuate nucleus to the paraventricular nucleus have
been implicated in the control of feeding, previous studies have shown that few of these
neurones are activated by GHS. Instead, the majority of neurones activated by GHS appear to
project to the median eminence and not to the paraventricular nucleus. These neurones express
NPY, but exactly what their functional role is remains to be determined.
In summary, in vitro, GHS activates neurones in the arcuate nucleus and the ventromedial
hypothalamic nucleus whereas somatostatin and NPY inhibit these neurones. In both brain
regions, many of neurones that were activated by GHS were also inhibited by NPY. I present a
hypothesis to explain why GHS activates arcuate neurones but not ventromedial hypothalamic
neurones in vivo. The immunohistochemistry study that applied the NPY Y1 receptor
antagonist, revealed that ventromedial hypothalamic neurones were prevented from excitatory
effect of GHS by NPY. The immunohistochemistry results also suggest that neurones in the
ventromedial hypothalamic nucleus were affected by NPY release more than arcuate neurones.
As well as, systemic treatment with GHRP-6 resulted in inhibition on ventromedial
hypothalamic neurones. Finally, we discovered that NPY neurones in the arcuate nucleus
increased NPY mRNA expression in response to food restriction but not in response to chronic
treatment ofGHRP-6, despite the orexigenic effects of GHRP-6.
Further studies
The expression of NPY mRNA was affected by long term fasting, but not by chronic central
treatment of GHRP-6. Though, orexigenic effect of chronic administration of the secretagogue
was significant. This suggests that there might be different brain regions that mediate hunger's
effects and activate food intake. This raises the question about which central pathways that
respond to hunger induced by chronic GHS. AGRP is among peptides speculated to play a role.
AGRP mRNA level in the arcuate nucleus was previously demonstrated to be increased in
parallel with NPY mRNA by central infusion of ghrelin every 12 h for 72 h (Kamegai et al.,
2001b). However, it is yet to be identified whether the expression of AGRP mRNA is altered
by a 7-day chronic administration of GHS. To understand the mechanism, in situ hybridisation
is needed for this purpose. Additionally, detection of up- and down-regulation of receptors for
160 CHAPTER 5
AGRP and NPY in hypothalamic brain regions in response to chronic administration of GHS
might be able explain the mechanism.
In addition, muscimol, a GABA receptor agonist, was previously found to amplified NPY-
induced food intake in sated rats (Pu et al., 1999). It was reported that a sub-population of
NPY-producing neurones in the arcuate nucleus co-produces GABA (Horvath et ah, 1997).
This GABA pathway might as well responds to chronic administration of GHS or negative
energy balance. For further studies, the expression of GABA mRNA in the arcuate nucleus
might be examined.
Orexin-containing neurones in the lateral hypothalamus were also significantly activated by
central administration of GHRP-6 (Lawrence et ah, 2002). The expression of orexin mRNA in
this brain area is also a subject to be investigated to clarify the central response to chronic
treatment of GHS or food restriction.
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